1
|
Sakoda K, Baba S. Technical Note: Novel imaging method to obtain gray matter-attenuated inversion recovery image using low-field magnetic resonance imaging systems. Radiography (Lond) 2024; 30:231-236. [PMID: 38035438 DOI: 10.1016/j.radi.2023.11.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2023] [Revised: 10/16/2023] [Accepted: 11/11/2023] [Indexed: 12/02/2023]
Abstract
INTRODUCTION The double inversion recovery (DIR) technique suppresses two types of tissue signals with different T1 values by applying two inversion recovery (IR) pulses with different inversion times (TI). In contrast, the double tissue suppression with multi-echo acquisition and single TI combining HIRE (DOMUST-HIRE) method, is a technique enabling the white-matter-attenuated inversion recovery (WAIR) images by setting one inversion time (TI) in a sequence based on the multi-echo method and subtracting the second echo image from the first echo image. Here, we propose a new sequence that can provide the gray-matter-attenuated inversion recovery image based on the DOMUST-HIRE method. METHODS In this small clinical study, we performed determination of optimal TI and physical evaluation by imaging a subject's head with T1WI and our proposed method for GAIR images. RESULTS Our proposed method could increase the contrast ratio and the contrast-to-noise ratio between white matter (WM) and gray matter (GM), whereas the signal-to-noise ratio WM and GM decreased than with T1WI method. CONCLUSIONS Our proposed method can be used to suppress GM and CSF signals. IMPLICATIONS FOR PRACTICE The use of our proposed method in low-field MRI systems could provide GAIR image.
Collapse
Affiliation(s)
- K Sakoda
- Department of Radiological Technology, Kagoshima Medical Technology College, Japan.
| | - S Baba
- Department of Radiological Technology, Kagoshima Medical Technology College, Japan
| |
Collapse
|
2
|
Abstract
Hyperkalemia is developed in a part of patients with aldosterone-producing adenoma (APA) after adrenalectomy, suspected to be due to the insufficiency of aldosterone secretion. The purpose of this study is to determine the frequency and characteristics of prolonged postoperative hypoaldosteronism (PPHA) using chemiluminescent enzyme immunoassay (CLEIA). We studied 58 patients with APA with long time after adrenalectomy and whose PAC was measured using a CLEIA kit. The PAC value measured using CLEIA was significantly lower than that of using RIA between two consecutive visits before and after the shift of measuring method of PAC (median [interquantile range], 123.0 [99.8-164.0] vs. 39.5 [15.8-64.2] pg/mL, p < 0.01). PAC was below the minimum limit of quantification (4.0 pg/mL) of the CLEIA kit at least once in nine patients (15.5%) who had PPHA. The PPHA group were older (mean ± standard deviation, 61.3 ± 8.5 vs. 50.5 ± 10.1 years, p < 0.01) and had lower eGFR (60.3 ± 14.0 vs. 82.3 ± 22.8 mL/min/1.73 m2, p < 0.01) than the non-PPHA group. The frequency of postoperative hyperkalemia (maximum serum potassium >5.5 mEq/L) was higher in the PPHA group than in the non-PPHA group (55.6% vs. 8.2%, p < 0.01). In conclusion, a few patients with APA long time after adrenalectomy had unmeasurable PAC using CLEIA. PPHA is likely to develop in patients with APA after adrenalectomy who are older and have impaired renal function. Additionally, PPHA is related to the occurrence of postoperative hyperkalemia.
Collapse
Affiliation(s)
- Norio Wada
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo 060-8604, Japan
| | - Shuhei Baba
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo 060-8604, Japan
| | - Hajime Sugawara
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo 060-8604, Japan
| | - Arina Miyoshi
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo 060-8604, Japan
| | - Shinji Obara
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo 060-8604, Japan
| |
Collapse
|
3
|
Wada N, Miyoshi A, Baba S, Sugawara H, Obara S. A case of subacute thyroiditis after influenza vaccination. Endocrinol Diabetes Metab Case Rep 2023; 2023:22-0364. [PMID: 37931407 PMCID: PMC9986373 DOI: 10.1530/edm-22-0364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2022] [Accepted: 01/11/2022] [Indexed: 11/08/2023] Open
Abstract
Summary A 40-year-old Japanese woman presented to the outpatient clinic with fever and palpitations 2 days after receiving the influenza vaccine (Influenza HA Vaccine 'KMB'®) following the second dose of coronavirus disease 2019 (COVID-19) vaccine (COVID-19 vaccine Moderna intramuscular injection®). At the first visit, the patient presented with a swollen thyroid gland with mild tenderness, and she was diagnosed with subacute thyroiditis (SAT) based on the presence of thyrotoxicosis (free T3: 5.42 pg/mL; free T4: 2.34 ng/dL; and thyroid-stimulating hormone (TSH): <0.01 μIU/mL), a high C-reactive protein level (5.77 mg/dL), a negative TSH receptor antibody, and characteristic ultrasound findings. The patient's human leukocyte antigen types were A2, A11, B35, B51, DR4, and DR1403. Prednisolone (15 mg/day) was given as an initial dose, after which the fever subsided, and the dose was tapered and discontinued after 6 weeks. The patient was thought to have developed SAT due to influenza vaccination. SAT after influenza vaccination may be overlooked. For patients with SAT, it is necessary to obtain information regarding their vaccination history. Learning points After influenza vaccination, subacute thyroiditis (SAT) may develop. If persistent fever, anterior neck pain, swelling, tenderness of the thyroid gland, and symptoms of thyrotoxicosis are observed immediately after vaccination for several viruses, including influenza, an examination to rule out the onset of SAT is recommended. Human leukocyte antigen type A2 (HLA-A2) and HLA-B35 may be linked to the development of SAT following influenza vaccination. The two doses of the coronavirus disease 2019 (COVID-19) vaccine given before the influenza vaccine may affect the onset of SAT.
Collapse
Affiliation(s)
- Norio Wada
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan
| | - Arina Miyoshi
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan
| | - Shuhei Baba
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan
| | - Hajime Sugawara
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan
| | - Shinji Obara
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan
| |
Collapse
|
4
|
Tabata K, Nishie A, Shimomura Y, Isoda T, Kitamura Y, Nakata K, Yamada Y, Oda Y, Ishigami K, Baba S. Prediction of pathological response to preoperative chemotherapy for pancreatic ductal adenocarcinoma using 2-[ 18F]-fluoro-2-deoxy-d-glucose positron-emission tomography. Clin Radiol 2022; 77:436-442. [PMID: 35410786 DOI: 10.1016/j.crad.2022.03.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2021] [Accepted: 03/02/2022] [Indexed: 12/24/2022]
Abstract
AIM To determine whether the pathological response to preoperative chemotherapy for pancreatic ductal adenocarcinoma (PDAC) can be predicted using 2-[18F]-fluoro-2-deoxy-d-glucose positron-emission tomography (F-18 FDG-PET). MATERIALS AND METHODS Twenty-eight patients with PDAC who underwent only neoadjuvant chemotherapy (NAC) before surgery were enrolled in the study. All patients had F-18 FDG-PET examinations before NAC. The resected specimen was pathologically evaluated according to the Classification of Pancreatic Carcinoma (7th edn). Patients were categorised into a non-response group and a response group based on the pathological findings. The non-response group (Grades 1a and 1b) showed ≤50% necrosis in the specimen, while the specimens of the response group (Grades 2-3) showed >50% necrosis. The maximum standardised uptake values (SUVmax) of the tumours on F-18 FDG-PET were measured. The mean values of SUVmax were compared between the two groups. The diagnostic performance of SUVmax in distinguishing the two groups was also evaluated using receiver operating characteristic analysis. RESULTS The mean SUVmax of the response group was higher than that of the non-response group (9.00 ± 1.78 versus 4.26 ± 2.35; p<0.001). The optimal cut-off value of SUVmax was 9.28 for distinguishing the two groups. The sensitivity, specificity, and accuracy for the prediction in the response group were 80%, 95.7%, and 92.9%, respectively. CONCLUSIONS SUVmax on F-18 FDG-PET may be useful as a biomarker to predict the pathological response to NAC in patients with PDAC.
Collapse
Affiliation(s)
- K Tabata
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku Fukuoka, 812-8582, Japan
| | - A Nishie
- Department of Radiology Informatics and Network, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku Fukuoka, 812-8582, Japan; Department of Radiology, Graduate School of Medical Science, University of the Ryukyus, 207, Uehara, Nishihara-cho, Okinawa, 903-0215, Japan.
| | - Y Shimomura
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku Fukuoka, 812-8582, Japan
| | - T Isoda
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku Fukuoka, 812-8582, Japan
| | - Y Kitamura
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku Fukuoka, 812-8582, Japan
| | - K Nakata
- Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku Fukuoka, 812-8582, Japan
| | - Y Yamada
- Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku Fukuoka, 812-8582, Japan
| | - Y Oda
- Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku Fukuoka, 812-8582, Japan
| | - K Ishigami
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku Fukuoka, 812-8582, Japan
| | - S Baba
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku Fukuoka, 812-8582, Japan
| |
Collapse
|
5
|
Murashita M, Wada N, Baba S, Sugawara H, Miyoshi A, Obara S. Subacute thyroiditis associated with thyrotoxic periodic paralysis after COVID-19 vaccination: a case report. Endocrinol Diabetes Metab Case Rep 2022; 2022:22-0236. [PMID: 35578985 PMCID: PMC9175599 DOI: 10.1530/edm-22-0236] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2022] [Accepted: 04/25/2022] [Indexed: 12/18/2022] Open
Abstract
Summary We report a 26-year-old Japanese man who visited our outpatient clinic presenting fever immediately after i.m. injection of the second dose of a coronavirus disease 2019 (COVID-19) vaccine (Moderna®). At the first visit, the patient had a fever of 37.7°C and a swollen thyroid gland with mild tenderness. He was diagnosed with subacute thyroiditis (SAT) based on the presence of thyrotoxicosis (free tri-iodothyronine, 32.3 pg/mL; free thyroxine, >7.77 ng/dL; and thyroid-stimulating hormone (TSH) < 0.01 μIU/mL), high C-reactive protein level (7.40 mg/dL), negative TSH receptor antibody, and characteristic ultrasound findings. His HLA types were A*02:01/24:02, B*15:11/35:01, Cw*03:03, DRB1*09:01/12:01, DQB1*03:03, and DPB1*05: 01/41:01. He was initially administered prednisolone 15 mg/day, following which the fever subsided. After 10 days, he developed limb weakness and could not walk. The serum potassium level decreased to 1.8 mEq/L, which confirmed the diagnosis of thyrotoxic periodic paralysis (TPP). Potassium supplementation was initiated. The muscle weakness gradually decreased. Prednisolone therapy was terminated 6 weeks after the first visit. His thyroid function returned to normal 5 months after the first visit, through a hypothyroid state. To our knowledge, this is the first reported case of TPP-associated SAT following COVID-19 vaccination. Persistent fever following vaccination should be suspected of SAT. Additionally, TPP may be associated with SAT in Asian male patients. Learning points Following coronavirus disease 2019 (COVID-19) vaccination, subacute thyroiditis may develop regardless of the vaccine type. If persistent fever, anterior neck pain, swelling and tenderness of thyroid gland, and symptoms of thyrotoxicosis are observed immediately after the COVID-19 vaccination, examination in consideration of the onset of subacute thyroiditis is recommended. HLA-B35 may be associated with the onset of subacute thyroiditis after the COVID-19 vaccination. Although rare, subacute thyroiditis can be associated with thyrotoxic periodic paralysis, especially in Asian men. Glucocorticoid therapy for subacute thyroiditis may induce thyrotoxic periodic paralysis through hypokalemia.
Collapse
Affiliation(s)
- Mone Murashita
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan
| | - Norio Wada
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan
| | - Shuhei Baba
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan
| | - Hajime Sugawara
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan
| | - Arina Miyoshi
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan
| | - Shinji Obara
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan
| |
Collapse
|
6
|
Osanami A, Kanda M, Sato T, Akazawa C, Baba S, Komatsu H, Murase K, Yamashita T, Yano T. Case report: Successful combination therapy with double-filtration plasmapheresis and rituximab under the condition of the use of a sensor-augmented pump for type B insulin resistance syndrome. Front Endocrinol (Lausanne) 2022; 13:997296. [PMID: 36157458 PMCID: PMC9500182 DOI: 10.3389/fendo.2022.997296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/18/2022] [Accepted: 08/22/2022] [Indexed: 11/26/2022] Open
Abstract
Type B insulin resistance syndrome (TBIR) is a rare disease characterized by refractory diabetes due to severe insulin resistance caused by anti-insulin receptor autoantibodies, and a standard treatment regimen for TBIR has not been established, leading to therapeutic difficulties and high mortality. Since TBIR is known to be associated with autoimmune diseases such as systemic lupus erythematosus (SLE), glucocorticoids are often used as key immunosuppressive agents. However, glucocorticoids have the potential to exacerbate the pathophysiology of TBIR by worsening insulin sensitivity, which leads to hyperglycemia and muscle wasting. Here, we report a case history of a 66-year-old man who was diagnosed as having TBIR in combination with SLE and Sjögren's syndrome with marked hyperglycemia, ketosis, and muscle wasting. He was successfully treated with combination therapy of double-filtration plasmapheresis (DFPP) and administration of the anti-CD20 monoclonal antibody rituximab without induction of glucocorticoid therapy while using a sensor-augmented insulin pump (SAP) to prevent hypoglycemia. Remission of diabetes was achieved without severe hypoglycemic events and his circulating insulin receptor antibodies became negative after seven months of initiation of these treatments. Based on the successful clinical courses of this case, our report suggests the possibility of an effective therapeutic regimen with DFPP and rituximab under the condition of the use of an SAP for a patient with TBIR without induction of glucocorticoids.
Collapse
Affiliation(s)
- Arata Osanami
- Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Masatoshi Kanda
- Department of Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Tatsuya Sato
- Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
- Department of Cellular Physiology and Signal Transduction, Sapporo Medical University School of Medicine, Sapporo, Japan
- *Correspondence: Tatsuya Sato,
| | - Chikako Akazawa
- Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Shuhei Baba
- Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Hiroaki Komatsu
- Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Kazuyuki Murase
- Department of Medical Oncology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Tomohisa Yamashita
- Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Toshiyuki Yano
- Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
| |
Collapse
|
7
|
Baba S, Yumoto R, Kawami M, Takano M. Functional expression of equilibrative and concentrative nucleoside transporters in alveolar epithelial cells. Pharmazie 2021; 76:416-421. [PMID: 34481531 DOI: 10.1691/ph.2021.1017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 09/29/2022]
Abstract
Equilibrative nucleoside transporters (ENTs) and concentrative nucleoside transporters (CNTs) mediate the cellular uptake of nucleosides and nucleobases across the plasma membrane and play important roles in the salvage pathways of nucleotide synthesis. However, information about nucleoside transport systems in the lung alveolar epithelial cells is limited. Therefore, in the present study, we examined the function and expression of nucleoside transporters using primary cultured alveolar type II cells and transdifferentiated type I-like cells. The uptake of uridine, a substrate for ENTs and CNTs, in type II and type I-like cells was time, temperature, and concentration dependent, and was inhibited by other nucleoside transporter substrates such as adenosine. Uridine uptake in both cells was insensitive to nanomolar concentrations of NBMPR, a potent ENT1 inhibitor, while it was inhibited by higher concentrations of NBMPR, suggesting that ENT2, but not ENT1, is involved in uridine uptake in these cells. Additionally, uridine uptake was higher in the presence of Na+ than in the absence of Na + and was partially inhibited by a CNT inhibitor phloridzin in these cells, suggesting that CNT is also involved in uridine uptake. In both cells, the mRNA expression of ENT1, ENT2, CNT2, and CNT3 was observed. Finally, the activity of uridine uptake was considerably higher in type II cells than in type I-like cells. In addition, the mRNA expression of ENT2, CNT2, and CNT3, but not ENT1, was lower in type I-like cells than in type II cells. These findings would help understand the functional roles of equilibrative and concentrative nucleoside transporters in alveolar epithelial cells.
Collapse
Affiliation(s)
- S Baba
- Department of Pharmaceutics and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - R Yumoto
- Department of Pharmaceutics and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - M Kawami
- Department of Pharmaceutics and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - M Takano
- Department of Pharmaceutics and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; takanom@hiroshima-u. ac. jp
| |
Collapse
|
8
|
Wada N, Baba S, Sugawara H, Miyoshi A, Obara S, Usubuchi H, Terae S. Laterality Diagnosis of Adrenal Vein Sampling for Primary Aldosteronism Using Aldosterone Alone. J Endocr Soc 2021. [PMCID: PMC8265960 DOI: 10.1210/jendso/bvab048.592] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Background: In adrenal vein sampling (AVS) for primary aldosteronism (PA), cortisol concentration is used to determine successful AVS, and laterality diagnosis is performed using a combination of aldosterone and cortisol concentrations. In this study, we examined the comparison with the conventional method when AVS was determined by aldosterone alone. Subjects and methods: We studied the data from 277 patients with PA who underwent AVS in Sapporo City General Hospital from July 2007 to April 2020. The patients with autonomous cortisol production were excluded. Using the blood samples from adrenal veins and inferior vena cava (IVC) after ACTH stimulation, the predicting ability of the left and right ratio of aldosterone concentration (aldosterone ratio, AR) for lateralization Index (LI) was examined by Receiver operating characteristic (ROC) analysis. The predicting abilities of the ratio of aldosterone concentration between adrenal vein and IVC (aldosterone index, AI) and aldosterone concentration for selectivity index (SI) and contralateral ratio (CR) were also examined by ROC analysis. Results: Six samples (0.01%) with SI <5 after ACTH stimulation those were determined unsuccessful AVS. The results of the area under the curve (AUC) in ROC analysis of aldosterone concentration and AI for prediction of SI>5 was 0.998, 0.990, respectively, p=0.39. The optimal cut-off values of aldosterone concentration and AI for prediction successful AVS were 1700 pg/ml (sensitivity 99.5%, specificity 100%), 7.44 (sensitivity 94.0%, specificity 100%), respectively. Seventy-two patients (27.3%) had LI >4 who were diagnosed as unilateral aldosterone excess. AR had 0.94 of AUC for prediction of LR >4. The optimal cut-off value of AR was 3.53 (sensitivity 86.1%, specificity 94.8%). Eighty-two patients (31.1%) had unilateral CR<1. The AUC of aldosterone concentration and AI for prediction of CR<1 was 0.96, 0.98, respectively, p=0.07. The optimal cut-off values of aldosterone concentration and AI were 13600 pg/ml, 42, respectively. The sensitivity and the specificity at the optimal cut-off points of aldosterone concentration and AI were 91.5%, 91.5% and 91.5%, 94.8%, respectively. Conclusions: The determination of successful AVS and unilateral result in AVS can be predicted using aldosterone alone. It was suggested that AR is useful for tentative interpretation in the cases where the results of aldosterone were previously reported and lateralizing diagnosis of the cases with autonomous cortisol production.
Collapse
Affiliation(s)
- Norio Wada
- Sapporo City General Hospital, SAPPORO, Japan
| | - Shuhei Baba
- Sapporo City General Hospital, SAPPORO, Japan
| | | | | | | | | | | |
Collapse
|
9
|
Maruddin F, Malaka R, Sabil S, Baba S, Amqam H, Taufik M. Types of Acid and Drying Method Differently Affect the Chemical Profile of Sodium Caseinate. JFQHC 2021. [DOI: 10.18502/jfqhc.8.1.5460] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Background: Sodium caseinate is a rich source of protein and minerals originating from animals. Numerous food and non-food products are made from sodium caseinate. The present study investigated the chemical components (moisture, crude protein, ash, and soluble crude protein) of sodium caseinate prepared by different acids and drying techniques.
Methods: A completely randomized factorial design was used by different acids including hydrochloric acid (HCl) and acetic acid, and also drying methods including oven (50 °C for 48 h) and freeze drying (-40 °C for 48 h). In each experimental group, sodium caseinate was obtained for determination of moisture, crude protein, ash, and soluble crude protein. Data were statistically evaluated using an ANOVA in SPSS 18.0.
Results: The interaction of both acids and drying methods significantly (p<0.01) affected moisture, crud protein, and ash content. HCl treatment coupled with freeze drying was the best combination, resulting in an appreciably higher content of crude protein (52.90%), moisture (5.38%), and soluble protein (0.85%).
Conclusion: The kinds of acid and drying method altered the chemically profile of sodium caseinate. The combination of HCl and freeze drying could be the considered as the best approach, resulting in good chemical characteristics of sodium caseinate.
Collapse
|
10
|
Wada N, Miyoshi A, Usubuchi H, Terae S, Shibayama Y, Takahashi B, Baba S, Sugawara H, Obara S. Prediction of unilateral hyperaldosteronism on adrenal vein sampling using captopril challenge test in patients with primary aldosteronism. Endocr J 2021; 68:45-51. [PMID: 32848105 DOI: 10.1507/endocrj.ej20-0329] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Captopril challenge test (CCT) is a simple and safe confirmatory test for primary aldosteronism (PA). We investigated the effectiveness of the indices after captopril administration for prediction of unilateral hyperaldosteronism (UHA) on adrenal vein sampling (AVS). We studied 238 patients with PA who had CCT and successful AVS between July 2007 and December 2019 in Sapporo City General Hospital. Receiver operating characteristic (ROC) curve analysis showed that the diagnostic performance for prediction of UHA on AVS in regard to the reduction rate of plasma aldosterone concentration (PAC) after captopril administration was inferior to aldosterone to renin ratio (ARR) and PAC (area under the ROC curve 0.72 vs. 0.84, 0.72 vs. 0.89, respectively, both p < 0.01). Based on the optimal cut-off values in ARR (897 pg/mL/ng/mL/h, sensitivity 64.6%, specificity 93.0%) and PAC (203 pg/mL, sensitivity 73.9%, specificity 93.0%) after captopril administration, the patients were divided into three groups: (1) both positive, (2) one positive, and (3) both negative. The prevalence of UHA on AVS in the three groups were 90.0%, 52.9%, and 7.3%, respectively. In the first group, 31 of 32 patients with unilateral nodular lesion on CT had an ipsilateral unilateral AVS. In conclusion, the combination of post-captopril ARR and PAC is useful for prediction of laterality diagnosis on AVS. AVS is strongly recommended in patients with both positive or one positive results for the optimal cut-off values of post-captopril ARR and PAC and is weakly recommended in patients with both negative results.
Collapse
Affiliation(s)
- Norio Wada
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo 060-8604, Japan
| | - Arina Miyoshi
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo 060-8604, Japan
| | - Hiroaki Usubuchi
- Department of Radiology, Sapporo City General Hospital, Sapporo 060-8604, Japan
| | - Satoshi Terae
- Department of Radiology, Sapporo City General Hospital, Sapporo 060-8604, Japan
| | - Yui Shibayama
- Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8648, Japan
| | - Bunya Takahashi
- Department of Diagnostic Imaging, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8648, Japan
| | - Shuhei Baba
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo 060-8604, Japan
| | - Hajime Sugawara
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo 060-8604, Japan
| | - Shinji Obara
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo 060-8604, Japan
| |
Collapse
|
11
|
Satake A, Yasuda S, Murase H, Yoshizumi R, Komaki H, Baba S, Kubota T, Ojio S, Nishigaki K, Minatoguchi S, Tanaka T, Okura H, Minatoguchi S. Muse cells, endogenous reparative pluripotent stem cells, are mobilized into the peripheral blood after percutaneous coronary intervention in patients with coronary artery disease. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Multilineage-differentiating stress enduring (Muse) cells, endogenous reparative pluripotent stem cells, are defined as stage-specific embryonic antigen 3+ (SSEA3+) and CD105+ double-positive cells. We previously reported that intravenously injected Muse cells home to the damaged heart and differentiate into cardiomyocytes and vessels, and reduce the infarct size and improve cardiac function in a rabbit model of acute myocardial infarction (AMI) (Circ Res 2018), and that endogenous Muse cells are mobilized into the peripheral blood in the acute phase of patients with AMI, which improve left ventricular (LV) function and attenuate LV remodeling in the chronic phase at 6 months (Circ J 2018). However, whether Muse cells are mobilized into the peripheral blood after percutaneous coronary intervention (PCI) in patients with coronary artery disease.
Methods
Muse cells in the peripheral blood was measured by fluorescence-activated cell sorting (FACS) as SSEA3+ and CD105+ double-positive cells in patients with coronary artery disease with 75% coronary stenosis who underwent PCI (n=18) with a mean age of 73.0±7.2 (14 male and 4 female). Blood samples were collected from the antecubital vein in patients with coronary artery disease before, and 1 and 24 h after PCI. Since the majority of Muse cells were detected in the monocyte area and few Muse cells if any were detected in the lymphocyte area, we counted the Muse cells in the monocyte area by FACS. The number of Muse cells was expressed as cells per 100 μL of blood, as follows: absolute number of Muse cells (/100 μL) = white blood cells (/100 μL) × monocytes (%) × SSEA3+/CD105+ double-positive cells (%).
Results
Typical case of SSEA3+/CD105+ double-positive Muse cells measured by FACS shows that majority of Muse cells exist in the monocyte area (Fig, 1-A). The number of Muse cells in the peripheral blood was significantly greater (p<0.05) at 1 h (58.6±23.8 /100 μL) or 24 h after PCI (69.7±43.1/100 μL) as compared with that before PCI (46.3±19.0/100 μL) (Fig. 1-B).
Conclusion
Muse cells, endogenous pluripotent stem cells, are mobilized into the peripheral circulating blood 1 h and 24 h after PCI in patients with coronary artery disease. Mobilized Muse cells after PCI might be contributing to repair the damaged coronary artery.
Figure 1
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- A Satake
- Gifu Municipal hospital, Gifu, Japan
| | - S Yasuda
- Gifu Municipal hospital, Gifu, Japan
| | - H Murase
- Gifu Municipal hospital, Gifu, Japan
| | | | - H Komaki
- Gifu Municipal hospital, Gifu, Japan
| | - S Baba
- Gifu Municipal hospital, Gifu, Japan
| | - T Kubota
- Gifu Municipal hospital, Gifu, Japan
| | - S Ojio
- Gifu Municipal hospital, Gifu, Japan
| | | | - S Minatoguchi
- Gifu University Graduate School of Medicine, Department of Cardiology, Gifu, Japan
| | - T Tanaka
- Gifu University Graduate School of Medicine, Department of Cardiology, Gifu, Japan
| | - H Okura
- Gifu University Graduate School of Medicine, Department of Cardiology, Gifu, Japan
| | | |
Collapse
|
12
|
Baba S, Miyoshi A, Obara S, Usubuchi H, Terae S, Sunahara M, Oshima T, Misawa K, Tsuji T, Takahashi B, Yamazaki Y, Sasano H, Wada N. A case of Williams syndrome with suspected coexisting ectopic aldosterone-producing tumor in the liver. Endocrinol Diabetes Metab Case Rep 2020; 2020:EDM200057. [PMID: 33434178 PMCID: PMC7576637 DOI: 10.1530/edm-20-0057] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2020] [Revised: 06/17/2020] [Accepted: 08/25/2020] [Indexed: 11/08/2022] Open
Abstract
SUMMARY A 31-year-old man with Williams syndrome (WS) was referred to our hospital because of a 9-year history of hypertension, hypokalemia, and high plasma aldosterone concentration to renin activity ratio. A diagnosis of primary aldosteronism (PA) was clinically confirmed but an abdominal CT scan showed no abnormal findings in his adrenal glands. However, a 13-mm hypervascular tumor in the posterosuperior segment of the right hepatic lobe was detected. Adrenal venous sampling (AVS) subsequently revealed the presence of an extended tributary of the right adrenal vein to the liver surrounding the tumor. Segmental AVS further demonstrated a high plasma aldosterone concentration (PAC) in the right superior tributary vein draining the tumor. Laparoscopic partial hepatectomy was performed. The resected tumor histologically separated from the liver was composed of clear cells, immunohistochemically positive for aldesterone synthase (CYP11B2), and subsequently diagnosed as aldosterone-producing adrenal adenoma. After surgery, his blood pressure, serum potassium level, plasma renin activity and PAC were normalized. To the best of our knowledge, this is the first report of WS associated with PA. WS harbors a high prevalence of hypertension and therefore PA should be considered when managing the patients with WS and hypertension. In this case, the CT findings alone could not differentiate the adrenal rest tumor. Our case, therefore, highlights the usefulness of segmental AVS to distinguish adrenal tumors from hepatic adrenal rest tumors. LEARNING POINTS Williams syndrome (WS) is a rare genetic disorder, characterized by a constellation of medical and cognitive findings, with a hallmark feature of generalized arteriopathy presenting as stenoses of elastic arteries and hypertension. WS is a disease with a high frequency of hypertension but the renin-aldosterone system in WS cases has not been studied at all. If a patient with WS had hypertension and severe hypokalemia, low PRA and high ARR, the coexistence of primary aldosteronism (PA) should be considered. Adrenal rest tumors are thought to arise from aberrant adrenal tissues and are a rare cause of PA. Hepatic adrenal rest tumor (HART) should be considered in the differential diagnosis when detecting a mass in the right hepatic lobe. Segmental adrenal venous sampling could contribute to distinguish adrenal tumors from HART.
Collapse
Affiliation(s)
- Shuhei Baba
- Departments of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan
| | - Arina Miyoshi
- Departments of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan
| | - Shinji Obara
- Departments of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan
| | | | - Satoshi Terae
- Radiology, Sapporo City General Hospital, Sapporo, Japan
| | | | | | | | - Takahiro Tsuji
- Pathology, Sapporo City General Hospital, Sapporo, Japan
| | - Bunya Takahashi
- Department of Diagnostic Imaging, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Yuto Yamazaki
- Department of Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Hironobu Sasano
- Department of Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Norio Wada
- Departments of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan
| |
Collapse
|
13
|
Takano M, Higashi M, Baba S, Kawami M, Yumoto R. Transport of ribavirin in human myelogenous leukemia cell line K562. Pharmazie 2020; 75:329-334. [PMID: 32635975 DOI: 10.1691/ph.2020.0440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 09/29/2022]
Abstract
The anticancer effect of ribavirin, a purine nucleoside analogue, has been studied using cultured cancer cells such as the human myelogenous leukemia cell line K562. In order to exert its pharmacological effect, ribavirin has to enter cancer cells. However, there is little information concerning the transport mechanism of ribavirin into K562 cells. In this study, therefore, we examined the uptake mechanism of ribavirin in K562 cells. The uptake of ribavirin in K562 cells was time- and temperature-dependent, and was saturable with a Km value of 1.5 mM. Ribavirin uptake was inhibited by nucleosides such as adenosine and uridine, and by inhibitors of equilibrative nucleoside transporter 1 (ENT1) such as S-(4-nitrobenzyl)-6-thioinosine and dipyridamole in a concentration-dependent manner. In addition, the expression of ENT1 mRNA in K562 cells was confirmed by real-time PCR. On the other hand, Na+-dependence of ribavirin uptake was not observed, suggesting the involvement of ENT1, but not Na+-dependent concentrative nucleoside transporters, in ribavirin uptake in K562 cells. Treatment of K562 cells with sodium butyrate induced erythroid differentiation, but ribavirin uptake activity and sensitivity of the uptake to various inhibitors were not different between native and differentiated K562 cells. These results suggest that ribavirin uptake into K562 cells is mainly mediated by ENT1, which may have a pivotal role in anticancer effect of ribavirin.
Collapse
Affiliation(s)
- M Takano
- Department of Pharmaceutics and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan;,
| | - M Higashi
- Department of Pharmaceutics and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - S Baba
- Department of Pharmaceutics and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - M Kawami
- Department of Pharmaceutics and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - R Yumoto
- Department of Pharmaceutics and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| |
Collapse
|
14
|
Shibayama Y, Wada N, Baba S, Obara S, Sakai H, Usubuchi H, Terae S, Nakamura A, Atsumi T. The risk factors for hepatic steatosis in patients with primary aldosteronism. Endocr J 2020; 67:623-629. [PMID: 32213734 DOI: 10.1507/endocrj.ej19-0600] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Patients with primary aldosteronism (PA) are complicated by metabolic syndrome more frequently than those without PA. Hyperaldosteronism has been reported to be associated with a higher prevalence of non-alcoholic fatty liver disease (NAFLD). We aimed to clarify the risk factors for hepatic steatosis in the two subtypes of PA, comparing the status of hepatic steatosis in each of these subtypes. This was a retrospective observational study. We enrolled patients with an aldosterone producing adenoma (APA) (n = 33) or idiopathic hyperaldosteronism (IHA) (n = 56). Hepatic fat content was evaluated using the ratio of liver to spleen (L/S) X-ray attenuation on unenhanced computed tomography. L/S ratio <1.0 was utilized for assessing as hepatic steatosis. Age, sex distribution, visceral fat percentage (VF%), and visceral fat area (VFA) did not differ between patients with the two PA subtypes. The percentages of patients with L/S ratio <1.0 was not different between the two subtypes (APA: 21.2 % (7/33) vs. IHA: 19.6 % (11/56), p = 1.00). In both subtypes, the L/S ratio negatively correlated with VF% (APA: r = -0.66, p < 0.001; IHA: r = -0.66, p < 0.001) and with VFA (APA: r = -0.44, p < 0.01; IHA: r = -0.37, p < 0.01). The status of hepatic steatosis, evaluated using L/S ratio, did not differ between patients with APA or IHA. Hepatic steatosis was affected by the amount of visceral fat.
Collapse
Affiliation(s)
- Yui Shibayama
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, 060-8604 Sapporo, Japan
- Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, 060-8648 Sapporo, Japan
| | - Norio Wada
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, 060-8604 Sapporo, Japan
| | - Shuhei Baba
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, 060-8604 Sapporo, Japan
| | - Shinji Obara
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, 060-8604 Sapporo, Japan
| | - Hidetsugu Sakai
- Department of Radiation Technology, Sapporo City General Hospital, 060-8604 Sapporo, Japan
| | - Hiroaki Usubuchi
- Department of Diagnostic Radiology, Sapporo City General Hospital, 060-8604 Sapporo, Japan
| | - Satoshi Terae
- Department of Diagnostic Radiology, Sapporo City General Hospital, 060-8604 Sapporo, Japan
| | - Akinobu Nakamura
- Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, 060-8648 Sapporo, Japan
| | - Tatsuya Atsumi
- Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, 060-8648 Sapporo, Japan
| |
Collapse
|
15
|
Shibayama Y, Wada N, Baba S, Obara S, Sakai H, Usubuchi H, Terae S, Kameda H, Nakamura A, Atsumi T. SAT-177 Relationship Between Visceral Fat and the Position of Adrenal Glands in Cranial-Caudal Direction in Patients with Primary Aldosteronism. J Endocr Soc 2020. [PMCID: PMC7208883 DOI: 10.1210/jendso/bvaa046.210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/04/2022] Open
Abstract
Context: Adrenal glands locate at the retroperitoneal space and could be affected their positions by some factors. Adrenal glands being surrounded by visceral adipose tissue (VAT), we have hypothesized that the VAT amount influences the position of adrenal glands in cranial-caudal direction. In patients with primary aldosteronism (PA), comprehending the position of adrenal glands in cranial-caudal direction might be useful to predict the position of adrenal veins before performing adrenal venous sampling. Objectives: To clarify the influence of VAT amount on the position of adrenal glands, we investigated the correlation of visceral fat parameters with the position difference of adrenal glands in cranial-caudal direction in patients with PA. Materials and methods: This retrospective observational study included patients with PA according to the guidelines of both the Japan Endocrine Society and the Japan Society of Hypertension. Those with adrenal tumors more than 10 mm in diameter in computed tomography (CT) were excluded. We measured the position difference of the adrenal glands in cranial-caudal direction, from the top of right adrenal gland to the top of left adrenal gland by CT. We correlated visceral fat percentage (VF%), visceral fat area (VFA), and subcutaneous fat area (SCFA) evaluated by CT studies with the position difference of adrenal glands in cranial-caudal direction. Results: We analyzed 150 patients [male (n = 50), female (n = 100)]. Patients’ characteristics: Age was 54.8 ± 11.4, body mass index 24.9 ± 3.8 kg/m2, plasma aldosterone concentration 133.5 [101–176] pg/ml, plasma renin activity 0.3 [0.2–0.5] ng/ml/h, VF% 25.8 [19.8–33.6] %, VFA 88.3 [60.9–125.0] cm2, and SCFA was 147.4 [105.6–193.4] cm2 (mean ± SD, or median [interquartile range]). The position difference of adrenal glands in cranial-caudal direction was 9.7 ± 10.0 mm. In 120 patients (80.0%), left adrenal glands locate at the upper position comparing to right adrenal glands. In 19 patients (12.7%), right adrenal glands were positioned at the upper comparing to left adrenal glands. A positive correlation of VF%, VFA with the position difference of adrenal glands in cranial-caudal direction were shown (r = 0.451, p < 0.001, r = 0.426, p < 0.001, respectively). No significant correlation of SCFA with the position difference of adrenal glands in cranial-caudal direction was shown (r = 0.122, p = 0.139). In patients with more VAT amount, right adrenal glands locate at the upper position comparing to left adrenal glands. In patients with less VAT amount, left adrenal glands locate at the upper position comparing to right adrenal glands. Conclusions: Regardless of the variation of the position of adrenal gland on each side, the correlation was found between VAT and the position difference of adrenal glands in cranial-caudal direction in PA.
Collapse
Affiliation(s)
| | - Norio Wada
- Sapporo City General Hospital, Sapporo, Japan
| | - Shuhei Baba
- Sapporo City General Hospital, Sapporo, Japan
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Abstract
In adrenal venous sampling (AVS) for patients with primary aldosteronism (PA), adrenocorticotropic hormone (ACTH) stimulation generally increased the success rate. The effect of ACTH stimulation on the left-right differences of laterality diagnosis in AVS remains unclear. A total of 167 patients with PA underwent successful AVS were examined. Patients with autonomous cortisol secretion were excluded. The proportion of dominant side in AVS was compared before and after ACTH stimulation. Unilateral disease on AVS was defined as a lateralization index of more than 4, both before and after ACTH stimulation. Before ACTH stimulation, unilateral disease was more frequently observed on the right side than the left side (right 33.5% vs. left 13.8%, p < 0.01). After ACTH stimulation, unilateral disease was more frequently observed on the left side than the right side, without statistical significance (left 15.6% vs. right 10.8%, p = 0.20). Among the 56 patients who had right unilateral disease before ACTH stimulation, 17 patients (30.0%) also had right unilateral disease after ACTH stimulation. The affected side of AVS was changed from right unilateral to bilateral after ACTH stimulation in 34 (60.7%) out of 56 patients. These patients had milder PA and CT scans showed no nodular lesions on the right side. In AVS, ACTH stimulation not only decreased unilateral results but also shifted to the dominant side. Overestimation should be carefully considered when the surgical indication for the right adrenal gland was decided based on AVS results without ACTH stimulation.
Collapse
Affiliation(s)
- Arina Miyoshi
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo 060-8604, Japan
| | - Norio Wada
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo 060-8604, Japan
| | - Shuhei Baba
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo 060-8604, Japan
| | - Shinji Obara
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo 060-8604, Japan
| | - Bunya Takahashi
- Department of Radiology, Sapporo City General Hospital, Sapporo 060-8604, Japan
| | - Hiroaki Usubuchi
- Department of Radiology, Sapporo City General Hospital, Sapporo 060-8604, Japan
| | - Satoshi Terae
- Department of Radiology, Sapporo City General Hospital, Sapporo 060-8604, Japan
| |
Collapse
|
17
|
Shibayama Y, Wada N, Baba S, Obara S, Iwasaki R, Nakajima H, Sakai H, Usubuchi H, Terae S, Miyano Y, Nakamura A, Atsumi T. SAT-002 Measurement of Visceral Fat Using Computed Tomography in Two Subtypes of Primary Aldosteronism. J Endocr Soc 2019. [PMCID: PMC6551971 DOI: 10.1210/js.2019-sat-002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Context: A strong association between excess visceral fat and the presence of metabolic factors, hypertension and type 2 diabetes have been demonstrated. Patients with primary aldosteronism (PA) are complicated by metabolic syndrome more frequently than those without PA. Aldosterone-induced mineralocorticoid receptor activation has been reported to impair insulin sensitivity in adipocytes and skeletal muscle. An excess of visceral fat has been hypothesized to cause an elevation of aldosterone secretion, and to cause insulin resistance in patients with PA. Objectives: To clarify the role of visceral fat in the pathophysiology of PA, we investigated the correlation of visceral fat parameters with plasma aldosterone concentration (PAC), and the correlation of visceral fat parameters with homeostasis model assessment insulin resistance (HOMA-R) in patients with PA. Materials and methods: This retrospective observational study comprised 131 patients diagnosed with PA between 2007 and 2017 at Sapporo City General Hospital. We divided participants into two subtypes, aldosterone producing adenoma (APA, n = 47) and idiopathic hyperaldosteronism (IHA, n = 84), utilizing adrenal venous sampling. We excluded patients with suspected autonomous cortisol secretion, defined as serum cortisol levels ≧ 3 μg/dL after a 1-mg dexamethasone suppression test. We analyzed the correlations of visceral fat percentage (VF%), visceral fat area (VFA) evaluated by computed tomography studies and PAC, and the correlations of VF% and VFA with HOMA-R in each subtype group. Results: Age and sex distribution was not different between patients with APA and patients with IHA (p = 0.85, p = 0.18, respectively). PAC was significantly higher in patients with APA than patients with IHA (p < 0.001). Serum potassium levels were significantly lower in patients with APA than patients with IHA (p < 0.001). Body mass index was not different between these two subtypes (p = 0.87). VF% was significantly higher in patients with IHA than in those with APA (p = 0.02). The number of patients treated as type 2 diabetes mellitus with oral medicine, HbA1c, and HOMA-R were not different between these two subtypes (p =0.76, p =0.22, p = 0.12, respectively). Patients with IHA showed a positive correlation of VF% with PAC (r = 0.377, p < 0.001), and VFA with PAC (r = 0.443, p < 0.001). In contrast, patients with APA showed no significant correlation of VF% and VFA with PAC. Patients with APA and patients with IHA showed a positive correlation of VF% and VFA with HOMA-R. Conclusions: Between two subtypes of PA, the association of visceral fat on insulin resistance was not different. The association of visceral fat on PAC was different in two subtypes of PA. Only in patients with IHA, visceral fat may play a role in regulation of aldosterone secretion.
Collapse
Affiliation(s)
- Yui Shibayama
- Hokkaido University Hospital, Internal Medicine II, Sapporo, , Japan
| | - Norio Wada
- Sapporo City General Hospital, Sapporo, , Japan
| | - Shuhei Baba
- Sapporo City General Hospital, Sapporo, , Japan
| | | | - Ren Iwasaki
- Sapporo City General Hospital, Sapporo, , Japan
| | | | | | | | | | - Yukie Miyano
- Hokkaido University Hospital, Internal Medicine II, Sapporo, , Japan
| | - Akinobu Nakamura
- Hokkaido University Hospital, Internal Medicine II, Sapporo, , Japan
| | - Tatsuya Atsumi
- Hokkaido University Hospital, Internal Medicine II, Sapporo, , Japan
| |
Collapse
|
18
|
Wada N, Baba S, Takahashi K, Miyoshi A, Obara S, Takahashi B, Usubuchi H, Terae S, Sunahara M, Oshima T, Misawa K, Yamazaki Y, Sasano H. SAT-073 A Case of Williams Syndrome Associated with Aldosterone Producing Adrenal Adenoma Mimicking Hepatic Adrenal Rest Tumor. J Endocr Soc 2019. [PMCID: PMC6552179 DOI: 10.1210/js.2019-sat-073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Background: Williams syndrome (WS) is a microdeletion disorder caused by heterozygous loss of approximately 1.5-Mb pairs of DNA from chromosome 7. Patients with WS have a characteristic constellation of medical and cognitive findings, with a hallmark feature of generalized arteriopathy presenting as stenoses of elastic arteries and hypertension. We present here a case of WS associated with primary aldosteronism (PA), whose source of aldosterone excess was difficult to locate. Clinical case: A 31-year-old man suspected having PA was referred to our Hospital. He was diagnosed as having Williams syndrome at 2 months of age. He had been hypertensive for 9 years. At the age of 31 years old, low serum potassium (K) and high aldosterone to renin ratio were pointed out. His plasma renin activity (PRA) was 0.2 ng/ml/h, plasma aldosterone concentration (PAC) was 456 pg/ml, serum K level was 3.1 mEq/l at admission. Diagnosis of PA was confirmed according to positive captopril challenge test. CT scan revealed a 13mm tumor with low density in posterosuperior segment of right hepatic lobe, but adrenal tumor was not detected. Venography of adrenal vein sampling (AVS) showed an extended tributary of the right adrenal vein to the liver that surrounded the tumor. Segmental AVS was performed for right adrenal vein and showed a high value of PAC (377000 pg/ml) in superior tributary which was drained from the tumor. PAC in other tributaries of right adrenal vein and left adrenal vein was suppressed. Laparoscopic partial hepatectomy was performed as a liver tumor. After surgery, serum K level was normalized, PAC decreased to 67 pg/ml. Pathological examination revealed a golden-yellow tumor separated from the liver by fibrous septum. The tumor was attached to an adrenal cortex embedded in the liver. The tumor was composed of clear cells, positive for 3βHSD2 and CYP11B2 using immunohistochemistry, diagnosed as aldosterone producing adrenal adenoma. Conclusion: To the best of our knowledge, this is the first report of WS associated with PA. Since WS is a disease with high prevalence of hypertension, measurement of PRA and PAC for screening of PA is recommended for patients with WS associated with hypertension. According to CT findings, hepatic adrenal rest tumor was suspected because the tumor was not continuous with the right adrenal gland, but pathological findings demonstrated that an adrenal adenoma was originated from right adrenal cortex rather embedded in the liver. Segmental AVS was useful to distinguish adrenal tumor from hepatic adrenal rest tumor.
Collapse
Affiliation(s)
- Norio Wada
- Sapporo City General Hospital, Sapporo, , Japan
| | - Shuhei Baba
- Sapporo City General Hospital, Sapporo, , Japan
| | | | | | | | | | | | | | | | | | | | - Yuto Yamazaki
- Pathology, Tohoku University Graduate School of Medicine, Sendai, , Japan
| | - Hironobu Sasano
- Dept of Pathology, Tohoku University Graduate School of Medicine, Sendai, , Japan
| |
Collapse
|
19
|
Baba S, Dagong M, Sohrah S. Factors Affecting the Adoption of Agricultural By-Products as Feed by Beef Cattle Farmers in Maros Regency of South Sulawesi, Indonesia. Trop Anim Sci J 2019. [DOI: 10.5398/tasj.2019.42.1.76] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
20
|
Yoshihara S, Baba S, Kanemaru A, Ichikawa T. Craniofacial penetration by a wooden stick. Eur Ann Otorhinolaryngol Head Neck Dis 2019; 136:393-395. [PMID: 30878510 DOI: 10.1016/j.anorl.2018.07.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2018] [Revised: 07/10/2018] [Accepted: 07/23/2018] [Indexed: 11/28/2022]
Abstract
INTRODUCTION Penetrating craniofacial injuries caused by stick-like foreign bodies occur as a result of accidents particularly in children, and often lead to significant morbidity. CASE SUMMARY We describe a 5-year-old boy who sustained facial trauma after falling on a wooden stick which penetrated his left cheek. At the initial visit, his vital and neurological signs were normal. However, the stick had penetrated the frontal lobe to a depth of 3cm via the orbital cavity and the anterior skull base. The stick was successfully removed while visualizing the anterior skull base in an endoscopic transethmoidal approach. A follow-up examination one year after the accident demonstrated normal visual acuity and ocular motility, with no diplopia, tearing or pain. DISCUSSION Penetrating facial injuries caused by stick-like objects carry a significantly higher risk of serious neurological involvement. Even if penetrating facial injuries sometimes appear trivial, the external injury site is often insufficient to determine the position of the object within the head. Although the cheek is a rare entry site for intracranial injuries, the extent of damage should be assessed fully before attempting removal.
Collapse
Affiliation(s)
- S Yoshihara
- Department of Otorhinolaryngology - Head and Neck Surgery, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan; Department of Otolaryngology, Tokyo Metropolitan Children's Medical Center, 2-8-29 Musashidai, Fuchu-City, Tokyo 183-8561, Japan.
| | - S Baba
- Department of Otorhinolaryngology - Head and Neck Surgery, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan; Department of Otolaryngology, Tokyo Metropolitan Children's Medical Center, 2-8-29 Musashidai, Fuchu-City, Tokyo 183-8561, Japan
| | - A Kanemaru
- Department of Otorhinolaryngology - Head and Neck Surgery, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan; Department of Otolaryngology, Tokyo Metropolitan Children's Medical Center, 2-8-29 Musashidai, Fuchu-City, Tokyo 183-8561, Japan
| | - T Ichikawa
- Dolphin west-Funabashi ENT clinic, 2-335-1 Katsushika, Funabashi-City, Chiba 273-0032, Japan
| |
Collapse
|
21
|
Kobayashi K, Taira N, Sawaki M, Sagawa N, Baba S, Saito T, Kawahara T, Hagiwara Y, Uemura Y, Shimozuma K, Ohashi Y, Mukai H. Abstract P2-13-02: Patient-reported outcomes with trastuzumab monotherapy versus trastuzumab plus standard chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients (RESPECT): A randomized, open-label, phase 3 clinical trial. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-13-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
OBJECTIVE: The RESPECT trial compared 1-year trastuzumab monotherapy with trastuzumab plus standard chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients. Primary objective of this study was to verify the noninferiority of 1-year trastuzumab monotherapy to trastuzumab plus chemotherapy in terms of disease free survival, and the planned analysis showed that the difference of restricted mean survival time between two groups at 3 years was 0.45 months (reported by Sawaki at ASCO2018). This report assesses the patients-reported outcomes and health-related quality of life (HRQoL).
PATIENTS AND METHODS: The study was done at 99 hospitals in Japan. Elderly women (70 to 80 years old) with HER2-positive, stageI-IIIA invasive breast cancer treated by surgery with clear resection margins were randomly assigned to receive either 1-year trastuzumab or 1-year trastuzumab plus standard chemotherapy, stratified by age, hormone-receptor status, pathological lymph node metastasis and institution. Patients completed questionnaires at baseline, 2 months, 1year, and 3 years after protocol treatment started. The primary outcome was global HRQoL assessed using Functional Assessment of Cancer Therapy-General (FACT-G) total score, and secondary outcomes were chemotherapy-induced peripheral neuropathy (CIPN), instrumental activities of daily living (IADL), anxiety, depression, and subjective happiness. We did the analyses by intention to treat, including patients who completed questionnaires at baseline before start of protocol treatment, and 5point or more change is meaningful in FACT-G total score. This study is registered with ClinicalTrials.gov, NCT01104935.
RESULTS: Between Oct 2009 and Oct 2014, 275 patients were enrolled in the study, of whom 9 patients were excluded: 135 assigned to trastuzumab monotherapy and 131 assigned to trastuzumab plus chemotherapy. We detected significant difference between treatment groups for: clinically meaningful HRQoL deterioration rate at 2 months (31% for trastuzumab monotherapy vs 48% for trastuzumab plus chemotherapy; p=0.016) and at 1year (19% vs 38%; p=0.009), clinically meaningful HRQoL improvement rate at 2 months (38% for trastuzumab monotherapy vs 15% for trastuzumab plus chemotherapy; p<0.01) and at 1year (43% vs 25%; p=0.021), severe sensory CIPN rate at 2months (1.9% for trastuzumab monotherapy vs 14.4% for trastuzumab plus chemotherapy; p=0.001), IADL score at 1year (11.97 for trastuzumab monotherapy vs 11.54 for trastuzumab plus chemotherapy; p<0.042), Hospital Anxiety and Depression Scale score at 2months (8.92 for trastuzumab monotherapy vs 10.79 for trastuzumab plus chemotherapy; p<0.003), and subjective happiness score at 1year (12.8 for trastuzumab monotherapy vs 11.8 for trastuzumab plus chemotherapy; p<0.024).
CONCLUSION: Given the small advantage of adjuvant trastuzumab plus chemotherapy compared to trastuzumab monotherapy for elderly HER-2 positive breast cancer women, decisions about treatment should be informed by the risk for adverse health effects associated with chemotherapy.
Citation Format: Kobayashi K, Taira N, Sawaki M, Sagawa N, Baba S, Saito T, Kawahara T, Hagiwara Y, Uemura Y, Shimozuma K, Ohashi Y, Mukai H. Patient-reported outcomes with trastuzumab monotherapy versus trastuzumab plus standard chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients (RESPECT): A randomized, open-label, phase 3 clinical trial [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-13-02.
Collapse
Affiliation(s)
- K Kobayashi
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Sagara Hospital, Kagoshima, Japan; Japanese Red Cross Saitama Hospital, Saitama, Japan; Clinical Research Support Center, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; College of Life Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - N Taira
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Sagara Hospital, Kagoshima, Japan; Japanese Red Cross Saitama Hospital, Saitama, Japan; Clinical Research Support Center, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; College of Life Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - M Sawaki
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Sagara Hospital, Kagoshima, Japan; Japanese Red Cross Saitama Hospital, Saitama, Japan; Clinical Research Support Center, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; College of Life Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - N Sagawa
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Sagara Hospital, Kagoshima, Japan; Japanese Red Cross Saitama Hospital, Saitama, Japan; Clinical Research Support Center, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; College of Life Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - S Baba
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Sagara Hospital, Kagoshima, Japan; Japanese Red Cross Saitama Hospital, Saitama, Japan; Clinical Research Support Center, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; College of Life Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - T Saito
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Sagara Hospital, Kagoshima, Japan; Japanese Red Cross Saitama Hospital, Saitama, Japan; Clinical Research Support Center, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; College of Life Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - T Kawahara
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Sagara Hospital, Kagoshima, Japan; Japanese Red Cross Saitama Hospital, Saitama, Japan; Clinical Research Support Center, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; College of Life Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - Y Hagiwara
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Sagara Hospital, Kagoshima, Japan; Japanese Red Cross Saitama Hospital, Saitama, Japan; Clinical Research Support Center, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; College of Life Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - Y Uemura
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Sagara Hospital, Kagoshima, Japan; Japanese Red Cross Saitama Hospital, Saitama, Japan; Clinical Research Support Center, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; College of Life Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - K Shimozuma
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Sagara Hospital, Kagoshima, Japan; Japanese Red Cross Saitama Hospital, Saitama, Japan; Clinical Research Support Center, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; College of Life Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - Y Ohashi
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Sagara Hospital, Kagoshima, Japan; Japanese Red Cross Saitama Hospital, Saitama, Japan; Clinical Research Support Center, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; College of Life Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| | - H Mukai
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Sagara Hospital, Kagoshima, Japan; Japanese Red Cross Saitama Hospital, Saitama, Japan; Clinical Research Support Center, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; College of Life Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan
| |
Collapse
|
22
|
Takahashi M, Sawaki M, Hagiwara Y, Uemura Y, Kawahara T, Shimozuma K, Ohashi Y, Saito T, Baba S, Kobayashi K, Mukai H, Taira N. Abstract P1-11-21: Analysis of cognitive function in elderly HER2-positive breast cancer patients receiving either trastuzumab monotherapy or trastuzumab plus chemotherapy as a postoperative adjuvant treatment: A cognitive function sub-study of a randomized, open-label, phase 3 clinical trial (RESPECT trial). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-11-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
OBJECTIVE: The effect of trastuzumab(Tmab) or chemotherapy on cognitive function has not been fully understood, especially in elderly breast cancer patients. The RESPECT trial compared 1-year(yr) Tmab monotherapy with Tmab plus standard chemotherapy as adjuvant therapy in elderly patients with HER2-positive breast cancer. The primary objective was to verify the noninferiority of 1-yr Tmab monotherapy compared to Tmab plus chemotherapy in terms of disease-free survival, and the planned analysis showed that the difference of restricted mean survival time between two groups at 3 yrs was 0.45 months (Sawaki at ASCO2018). The goal of this report was to assess the impact of the treatment groups on longitudinal cognitive function.
PATIENTS AND METHODS: The study was performed with patients from 99 hospitals in Japan. Elderly women with HER2-positive, stage I-IIIA invasive breast cancer surgery treated with clear resection margins were randomly assigned to either receive 1-yr Tmab or 1-yr Tmab plus standard chemotherapy. 15 institutions participated in the cognitive sub-study. Cognitive function was assessed using the Mini-Mental State Examination (MMSE) at baseline and at 1 and 3 yrs after treatment. The primary outcome was the amount of change in the MMSE score from the baseline. A linear mixed-effects model was used for comparisons of change in the MMSE score between groups, controlling for time and baseline score. Secondary outcomes were the proportion of both suspected mild dementia (MMSE≤27) and dementia (MMSE≤23) at each time point.
RESULTS: Between October 2009 and October 2014, 275 patients were enrolled in the RESPECT trial, and 57 patients were enrolled in the cognitive function sub-study with 2 patients subsequently excluded. The 55-patient sub-study comprised 29 patients assigned to the Tmab monotherapy group and 26 patients assigned to the Tmab plus chemotherapy group. Primary analysis revealed that change in the MMSE score was not significantly different between the two groups (difference −0.6 at 1 yr and −0.9 at 3 yrs; p=0.136), whereas the baseline score was the only significant factor that had an effect on the amount of change in the MMSE score (p<0.001). The proportions of suspected mild dementia at baseline, and at 1 yr and 3 yrs were 15.4, 32.0, and 41.7% in the Tmab monotherapy group, and 45.8, 17.6, and 28.6% in the Tmab plus chemotherapy group. The proportions of suspected mild dementia at baseline were significantly higher in the Tmab plus chemotherapy group (p=0.04). The proportions of suspected dementia at baseline, and at 1 yr and 3 yrs were 0%, 0%, and 4.2% in the Tmab monotherapy group, and 4.2%, 0%, and 4.8% in the Tmab plus chemotherapy group. There were no significant differences in the proportions of suspected dementia between the treatment groups at each time point.
CONCLUSION: Postoperative chemotherapy for elderly breast cancer patients was considered to have little effect on the onset of dementia during the follow-up period of 3 yrs. Further long-term observation is necessary to obtain a significant conclusion.
Citation Format: Takahashi M, Sawaki M, Hagiwara Y, Uemura Y, Kawahara T, Shimozuma K, Ohashi Y, Saito T, Baba S, Kobayashi K, Mukai H, Taira N. Analysis of cognitive function in elderly HER2-positive breast cancer patients receiving either trastuzumab monotherapy or trastuzumab plus chemotherapy as a postoperative adjuvant treatment: A cognitive function sub-study of a randomized, open-label, phase 3 clinical trial (RESPECT trial) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-11-21.
Collapse
Affiliation(s)
- M Takahashi
- NHO Hokkaido Cancer Center, Sapporo, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Clinical Research Support Center, The University of Tokyo Hospital, Tokyo, Japan; College of Life Sciences, Ritsumeikan University, Kusatsu, Japan; Chuo University, Tokyo, Japan; Japanese Red Cross Saitama Hospital, Saitama, Japan; Sagara Hospital, Kagoshima, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Okayama University Hospital, Okayama, Japan
| | - M Sawaki
- NHO Hokkaido Cancer Center, Sapporo, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Clinical Research Support Center, The University of Tokyo Hospital, Tokyo, Japan; College of Life Sciences, Ritsumeikan University, Kusatsu, Japan; Chuo University, Tokyo, Japan; Japanese Red Cross Saitama Hospital, Saitama, Japan; Sagara Hospital, Kagoshima, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Okayama University Hospital, Okayama, Japan
| | - Y Hagiwara
- NHO Hokkaido Cancer Center, Sapporo, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Clinical Research Support Center, The University of Tokyo Hospital, Tokyo, Japan; College of Life Sciences, Ritsumeikan University, Kusatsu, Japan; Chuo University, Tokyo, Japan; Japanese Red Cross Saitama Hospital, Saitama, Japan; Sagara Hospital, Kagoshima, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Okayama University Hospital, Okayama, Japan
| | - Y Uemura
- NHO Hokkaido Cancer Center, Sapporo, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Clinical Research Support Center, The University of Tokyo Hospital, Tokyo, Japan; College of Life Sciences, Ritsumeikan University, Kusatsu, Japan; Chuo University, Tokyo, Japan; Japanese Red Cross Saitama Hospital, Saitama, Japan; Sagara Hospital, Kagoshima, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Okayama University Hospital, Okayama, Japan
| | - T Kawahara
- NHO Hokkaido Cancer Center, Sapporo, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Clinical Research Support Center, The University of Tokyo Hospital, Tokyo, Japan; College of Life Sciences, Ritsumeikan University, Kusatsu, Japan; Chuo University, Tokyo, Japan; Japanese Red Cross Saitama Hospital, Saitama, Japan; Sagara Hospital, Kagoshima, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Okayama University Hospital, Okayama, Japan
| | - K Shimozuma
- NHO Hokkaido Cancer Center, Sapporo, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Clinical Research Support Center, The University of Tokyo Hospital, Tokyo, Japan; College of Life Sciences, Ritsumeikan University, Kusatsu, Japan; Chuo University, Tokyo, Japan; Japanese Red Cross Saitama Hospital, Saitama, Japan; Sagara Hospital, Kagoshima, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Okayama University Hospital, Okayama, Japan
| | - Y Ohashi
- NHO Hokkaido Cancer Center, Sapporo, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Clinical Research Support Center, The University of Tokyo Hospital, Tokyo, Japan; College of Life Sciences, Ritsumeikan University, Kusatsu, Japan; Chuo University, Tokyo, Japan; Japanese Red Cross Saitama Hospital, Saitama, Japan; Sagara Hospital, Kagoshima, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Okayama University Hospital, Okayama, Japan
| | - T Saito
- NHO Hokkaido Cancer Center, Sapporo, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Clinical Research Support Center, The University of Tokyo Hospital, Tokyo, Japan; College of Life Sciences, Ritsumeikan University, Kusatsu, Japan; Chuo University, Tokyo, Japan; Japanese Red Cross Saitama Hospital, Saitama, Japan; Sagara Hospital, Kagoshima, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Okayama University Hospital, Okayama, Japan
| | - S Baba
- NHO Hokkaido Cancer Center, Sapporo, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Clinical Research Support Center, The University of Tokyo Hospital, Tokyo, Japan; College of Life Sciences, Ritsumeikan University, Kusatsu, Japan; Chuo University, Tokyo, Japan; Japanese Red Cross Saitama Hospital, Saitama, Japan; Sagara Hospital, Kagoshima, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Okayama University Hospital, Okayama, Japan
| | - K Kobayashi
- NHO Hokkaido Cancer Center, Sapporo, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Clinical Research Support Center, The University of Tokyo Hospital, Tokyo, Japan; College of Life Sciences, Ritsumeikan University, Kusatsu, Japan; Chuo University, Tokyo, Japan; Japanese Red Cross Saitama Hospital, Saitama, Japan; Sagara Hospital, Kagoshima, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Okayama University Hospital, Okayama, Japan
| | - H Mukai
- NHO Hokkaido Cancer Center, Sapporo, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Clinical Research Support Center, The University of Tokyo Hospital, Tokyo, Japan; College of Life Sciences, Ritsumeikan University, Kusatsu, Japan; Chuo University, Tokyo, Japan; Japanese Red Cross Saitama Hospital, Saitama, Japan; Sagara Hospital, Kagoshima, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Okayama University Hospital, Okayama, Japan
| | - N Taira
- NHO Hokkaido Cancer Center, Sapporo, Japan; Aichi Cancer Center Hospital, Nagoya, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Clinical Research Support Center, The University of Tokyo Hospital, Tokyo, Japan; College of Life Sciences, Ritsumeikan University, Kusatsu, Japan; Chuo University, Tokyo, Japan; Japanese Red Cross Saitama Hospital, Saitama, Japan; Sagara Hospital, Kagoshima, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Okayama University Hospital, Okayama, Japan
| |
Collapse
|
23
|
Nishimura T, Yoshida K, Kawata Y, Takeuchi Y, Kakiuchi N, Shiozawa Y, Aoki K, Hirata M, Kataoka TR, Sakurai T, Baba S, Shiraishi Y, Chiba K, Takeuchi K, Haga H, Miyano S, Toi M, Ogawa S. Abstract P3-06-04: Clonal evolution of non-malignant proliferative lesions into breast cancers. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-06-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
[Introduction] Non-malignant proliferative lesions in the breast have been implicated in the development of invasive breast cancer. Previous studies showed that adjacent atypical proliferative lesions and breast cancers shared common genetic alterations, suggesting that these evolved from the same ancestral cell. However, the clonal structure of atypical proliferative lesions and their clonal dynamics during progression to cancer are poorly understood. In this study, we compared genetic profiles (with and without pathogenic germline mutations) of normal mammary ducts, non-malignant proliferative lesions, and cancer tissues from the same patients to illustrate the clonal evolution of cancer from a non-malignant epithelial cell.
[Methods] Multiple samples were collected from different proliferative lesions within the cancer-borne breast, including invasive cancers, using micro-dissection from formalin-fixed, paraffin-embedded surgical specimens. Somatic mutations and copy number alterations (CNAs) were then evaluated by whole exome sequencing.
[Results] We analyzed a total of 34 samples from 5 premenopausal females carrying estrogen receptor-positive cancers, where the samples were obtained from normal ducts (N = 6), non-atypical (N = 1) and atypical (N = 8) proliferative lesions, and non-invasive (N = 16) and invasive (N = 3) cancers. The number of somatic mutations per sample ranged from 1 to 276 and increased with disease progression, regardless of the germline mutation status. Two cases with bilateral cancers had a pathogenic germline mutation of either BRCA2 or TP53, where no somatic mutations or CNAs were shared by individual proliferative lesions, suggesting multifocal independent cancerous evolutions. By contrast, in the remaining three unilateral cases, no pathogenic germline mutations were detected, but all proliferative lesions, which were separated by a distance of 7-25 mm, shared one or more driver alterations, such as an AKT1 mutation (UID: KU01), concurrent 1q gain and 16q loss (der(1;16)) (UID: KU02), and a GATA3 mutation and der(1;16) (UID: KU03), while harboring private mutations and/or CNAs of their own. The phylogenetic analysis based on the number of shared mutations predicted an early origin of these founder mutations, which frequently predated decades before the onset of cancer.
[Conclusions] Our results suggest that early breast cancer development is shaped by the evolution of multiple precancerous clones. These clones are originated from a common ancestor that acquired a founder mutation long before the onset of cancer, followed by branching evolution of multiple clones that acquired additional driver mutations of their own, from which an invasive cancer ultimately develops. In hereditary cases, this process is thought to be substantially promoted multi-focally from within the entire breasts by a germline mutation shared by all mammary cells, frequently resulting in bilateral and/or multifocal breast cancers. Our findings provide unique insight into the early development of breast cancer.
Citation Format: Nishimura T, Yoshida K, Kawata Y, Takeuchi Y, Kakiuchi N, Shiozawa Y, Aoki K, Hirata M, Kataoka TR, Sakurai T, Baba S, Shiraishi Y, Chiba K, Takeuchi K, Haga H, Miyano S, Toi M, Ogawa S. Clonal evolution of non-malignant proliferative lesions into breast cancers [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-06-04.
Collapse
Affiliation(s)
- T Nishimura
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - K Yoshida
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Y Kawata
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Y Takeuchi
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - N Kakiuchi
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Y Shiozawa
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - K Aoki
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - M Hirata
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - TR Kataoka
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - T Sakurai
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - S Baba
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Y Shiraishi
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - K Chiba
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - K Takeuchi
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - H Haga
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - S Miyano
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - M Toi
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - S Ogawa
- Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| |
Collapse
|
24
|
Usman U, Abdulkadir A, El-Nafaty J, Bukar M, Baba S. Lithostratigraphy and geochemical characterization of limestone deposits around Kushimaga Area in Yobe Of North-Eastern Nigeria. Nig J Tech 2018. [DOI: 10.4314/njt.v37i4.5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
25
|
Shibayama Y, Wada N, Baba S, Miyano Y, Obara S, Iwasaki R, Nakajima H, Sakai H, Usubuchi H, Terae S, Nakamura A, Atsumi T. Relationship Between Visceral Fat and Plasma Aldosterone Concentration in Patients With Primary Aldosteronism. J Endocr Soc 2018; 2:1236-1245. [PMID: 30374468 PMCID: PMC6199893 DOI: 10.1210/js.2018-00187] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/19/2018] [Accepted: 09/12/2018] [Indexed: 12/27/2022] Open
Abstract
Context The involvement of visceral fat in aldosterone secretion has not been reported in patients with primary aldosteronism (PA). Patients with PA are complicated by metabolic syndrome more frequently than those without PA. An excess of visceral fat has been hypothesized to cause an elevation of aldosterone secretion in patients with PA. Objectives To clarify the role of visceral fat in the pathophysiology of PA, we investigated the correlation between plasma aldosterone concentration (PAC) and visceral fat parameters in patients with PA. Design This retrospective observational study comprised 131 patients diagnosed with PA between April 2007 and April 2017 at Sapporo City General Hospital. We divided participants into two PA subtypes, aldosterone-producing adenoma (APA; n = 47) and idiopathic hyperaldosteronism (IHA, n = 84), utilizing adrenal venous sampling. We analyzed the correlations of PAC with visceral fat percentage (VF%), visceral fat area (VFA), and subcutaneous fat area, by evaluating computed tomography studies in each subtype group. Results Patients with IHA showed a positive correlation of PAC with VF% (r = 0.377, P < 0.001) and VFA (r = 0.443, P < 0.001). The correlation was not evident in patients with APA. Conclusions This study revealed a relationship between visceral adipose tissue and aldosterone production only in patients with IHA.
Collapse
Affiliation(s)
- Yui Shibayama
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan.,Department of Rheumatology, Endocrinology, and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Norio Wada
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan
| | - Shuhei Baba
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan
| | - Yukie Miyano
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan
| | - Shinji Obara
- Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan
| | - Ren Iwasaki
- Department of Radiation Technology, Sapporo City General Hospital, Sapporo, Japan
| | - Haruka Nakajima
- Department of Radiation Technology, Sapporo City General Hospital, Sapporo, Japan
| | - Hidetsugu Sakai
- Department of Radiation Technology, Sapporo City General Hospital, Sapporo, Japan
| | - Hiroaki Usubuchi
- Department of Diagnostic Radiology, Sapporo City General Hospital, Sapporo, Japan
| | - Satoshi Terae
- Department of Diagnostic Radiology, Sapporo City General Hospital, Sapporo, Japan
| | - Akinobu Nakamura
- Department of Rheumatology, Endocrinology, and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Tatsuya Atsumi
- Department of Rheumatology, Endocrinology, and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| |
Collapse
|
26
|
Furuta T, Baba S, Yamade M, Uotani T, Kagami T, Suzuki T, Tani S, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K. High incidence of autoimmune gastritis in patients misdiagnosed with two or more failures of H. pylori eradication. Aliment Pharmacol Ther 2018; 48:370-377. [PMID: 29920721 DOI: 10.1111/apt.14849] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/23/2018] [Revised: 02/12/2018] [Accepted: 05/23/2018] [Indexed: 12/16/2022]
Abstract
BACKGROUND Although autoimmune gastritis (AIG) is generally considered relatively rare, we frequently encounter AIG among patients at to our hospital who have experienced at least two episodes of Helicobacter pylori eradication failure. AIMS We investigated the incidence of AIG in consecutive patients who consulted our department for H. pylori eradication with reference to eradication history. METHODS A total of 404 consecutive patients who visited the H. pylori-specific out-patient unit of our hospital from June 2015 to June 2017 were enrolled. Of these, 137 were treatment-naive, 47 had failed treatment once (single failure), and 220 had failed treatment twice or more (multiple failures) by 13 C-UBT. Gastroscopy was performed in all patients. Culture tests of gastric mucosal samples were performed for H. pylori and other bacteria positive for urease activity. Anti-parietal cell antibody (APCA) was measured. Patients with severe atrophy in the gastric corpus and positivity for APCA were diagnosed as having AIG. RESULTS A total of 43 patients were diagnosed as having AIG, of whom two were treatment-naive (1.5%, 2/137), 1 failed eradication once (2.1% 1/47), and 40 failed treatment at least twice (18.2%, 40/220). The incidence of AIG was significantly higher in the multiple failure group than in the single failure or treatment-naive groups. Urease-positive bacteria, such as Klebsiella pneumoniae and alpha-streptococcus, were identified in 33 of the 35 AIG patients who underwent culture testing. CONCLUSION AIG patients were often misdiagnosed as refractory to eradication therapy, probably because achlorhydria in AIG might allow urease-positive bacteria other than H. pylori to colonise the stomach, causing positive 13 C-UBT results.
Collapse
Affiliation(s)
- T Furuta
- Center for Clinical Research, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - S Baba
- Department of Diagnostic Pathology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - M Yamade
- First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - T Uotani
- First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - T Kagami
- First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - T Suzuki
- First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - S Tani
- Department of Endoscopic and Photodynamic Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - Y Hamaya
- First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - M Iwaizumi
- Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - S Osawa
- Department of Endoscopic and Photodynamic Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - K Sugimoto
- First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| |
Collapse
|
27
|
Yoshinaga D, Baba S, Makiyama T, Nishikomori R. 5326Can patient-derived iPSCs be applied to phenotypic cell-based high throughput screening assessment to distinguish between different types of long-QT syndrome? Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.5326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - S Baba
- Kyoto University, Pediatrics, Kyoto, Japan
| | - T Makiyama
- Kyoto University, Caridovascular medicine, Kyoto, Japan
| | | |
Collapse
|
28
|
Baba S, Katsumata Y, Okamoto Y, Kawaguchi Y, Hanaoka M, Kawasumi H, Yamanaka H. Reliability of the SF-36 in Japanese patients with systemic lupus erythematosus and its associations with disease activity and damage: a two-consecutive year prospective study. Lupus 2017; 27:407-416. [DOI: 10.1177/0961203317725586] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
We aimed to validate the reliability of the Medical Outcomes Study Short Form-36 (SF-36) among Japanese patients with systemic lupus erythematosus (SLE). Japanese patients with SLE ( n = 233) completed the SF-36 and other related demographic questionnaires, and physicians simultaneously completed the SLE Disease Activity Index 2000 (SLEDAI-2K) and the Systemic Lupus International Collaborating Clinics Damage Index (SDI). Patients were prospectively followed for a repeat assessment the following year. The SF-36 subscales demonstrated acceptable internal consistency (Cronbach’s α of 0.85–0.89), and an overall good test–retest reliability (intraclass correlation coefficient >0.70). The average baseline SF-36 subscale/summary scores except for “bodily pain” were significantly lower than those of the Japanese general population ( p < 0.05). The SDI showed an inverse correlation with the SF-36 subscale/summary scores except for “vitality” and “mental component summary” at baseline, whereas the SLEDAI-2K did not. In the second year, “social functioning” and “mental component summary” of the SF-36 deteriorated among patients whose SDI or SLEDAI-2K score increased (effect sizes < −0.20). In conclusion, the SF-36 demonstrated acceptable reliability among Japanese patients with SLE. Health-related quality of life measured by the SF-36 was reduced in Japanese patients with SLE and associated with disease damage, rather than disease activity.
Collapse
Affiliation(s)
- S Baba
- Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
| | - Y Katsumata
- Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
| | - Y Okamoto
- Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
| | - Y Kawaguchi
- Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
| | - M Hanaoka
- Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
| | - H Kawasumi
- Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
| | - H Yamanaka
- Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
| |
Collapse
|
29
|
Sakaguchi H, Miyazaki A, Matsumura Y, Shima Y, Baba S, Shiraishi I. P496Mid-term results of left ventricular apical pacing in pediatric patients with complete atrio-ventricular block. Europace 2017. [DOI: 10.1093/ehjci/eux141.218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
30
|
Matsumura Y, Sakaguchi H, Miyazaki A, Baba S, Hayama Y, Negishi J, Ohuchi H, Shiraishi I. P1462The importance of rhythm management among the CHD patients with atrial tachycardia. Europace 2017. [DOI: 10.1093/ehjci/eux158.089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Nakaya M, Yoshihara S, Yoshitomi A, Baba S. Endoscopic endonasal excision of nasal chondromesenchymal hamartoma with intracranial extension. Eur Ann Otorhinolaryngol Head Neck Dis 2017; 134:423-425. [PMID: 28385583 DOI: 10.1016/j.anorl.2016.05.014] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2015] [Accepted: 05/23/2016] [Indexed: 10/19/2022]
Abstract
INTRODUCTION Nasal chondromesenchymal hamartoma (NCMH) is an extremely rare benign hamartoma of the sinonasal tract, predominantly involving infants and young children. METHODS We report the case of a 3-year-old boy of NCMH with extension to anterior skull base. RESULTS The tumor was completely resected piece by piece via an endonasal endoscopic approach. There is no recurrence 3 years after operation. CONCLUSIONS We reported the case of NCMH extending to skull base was successfully resected by endonasal endoscopic approach.
Collapse
Affiliation(s)
- M Nakaya
- Department of Otolaryngology-Head and Neck Surgery, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashidai, Fuchu-shi, Tokyo 183-8524, Japan; Department of Otolaryngology, Tokyo Metropolitan Children's Medical Center, 2-8-29, Musashidai, Fuchu-shi, Tokyo 183-8561, Japan.
| | - S Yoshihara
- Department of Otolaryngology-Head and Neck Surgery, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashidai, Fuchu-shi, Tokyo 183-8524, Japan; Department of Otolaryngology, Tokyo Metropolitan Children's Medical Center, 2-8-29, Musashidai, Fuchu-shi, Tokyo 183-8561, Japan
| | - A Yoshitomi
- Department of Otolaryngology, Tokyo Metropolitan Children's Medical Center, 2-8-29, Musashidai, Fuchu-shi, Tokyo 183-8561, Japan
| | - S Baba
- Department of Otolaryngology, Tokyo Metropolitan Children's Medical Center, 2-8-29, Musashidai, Fuchu-shi, Tokyo 183-8561, Japan
| |
Collapse
|
32
|
|
33
|
Abdul-Kareem S, Baba S, Wahid MIA. Research in medical informatics. Health Informatics J 2016. [DOI: 10.1177/146045820000600209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Medical informatics is concerned with the application of computers in the medical and biological sciences and has been considered a field of research in its own right for more than twenty years. In Malaysia, however, there are very few published efforts in this area. To keep up with research activities carried out worldwide and to create expertise that will be in great demand once the Malaysian Multimedia Super Corridor (MSC) Telemedicine Flagship project is implemented, it is time that Malaysians involved themselves in medical informatics research activities. For this reason, we are proposing a project that will involve the application of an artificial neural network in the domain of cancer. As a prelude to our own research, we review current research in medical informatics. This paper subsequently proposes the use of an artificial neural networks as an alternative tool for investigating cancer survival.
Collapse
Affiliation(s)
- S. Abdul-Kareem
- Faculty of Computer Science and Information Technology, University of Malaya,
| | - S. Baba
- Multimedia Development Centre, University of Malaya
| | - M. I. A. Wahid
- Clinical Oncology Unit, University Hospital, University of Malaya
| |
Collapse
|
34
|
Abstract
The analysis of cancer survival is used to determine the efficiency of treatment programmes and protocols; it is also used to determine the type of treatment. At the individual level a prediction of cancer survival can help patients make informed decisions with regards to their quality of life and future finances. Currently available prediction methods apply to groups of people, and may not be adequate to predict treatment outcome for individual patients. This paper presents a conceptual model of a cancer knowledge base incorporating a computer-based predictor for survival. It proposes the use of an artificial neural network (ANN) as an alternative tool for investigating cancer survival. The focus of this research will be on nasopharyngeal carcinoma survival data collected in Malaysia.
Collapse
Affiliation(s)
- S. Abdul-Kareem
- Faculty of Computer Science and Information Technology, University of Malaya
| | - S. Baba
- Faculty of Computer Science and Information Technology, University of Malaya
| | | | - M. I. A. Wahid
- Clinical Oncology Unit, University Hospital, Kuala Lumpur,
| |
Collapse
|
35
|
Sakai N, Takehara Y, Yamashita S, Ohishi N, Kawaji H, Sameshima T, Baba S, Sakahara H, Namba H. Shear Stiffness of 4 Common Intracranial Tumors Measured Using MR Elastography: Comparison with Intraoperative Consistency Grading. AJNR Am J Neuroradiol 2016; 37:1851-1859. [PMID: 27339950 DOI: 10.3174/ajnr.a4832] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2015] [Accepted: 04/11/2016] [Indexed: 01/22/2023]
Abstract
BACKGROUND AND PURPOSE The stiffness of intracranial tumors affects the outcome of tumor removal. We evaluated the stiffness of 4 common intracranial tumors by using MR elastography and tested whether MR elastography had the potential to discriminate firm tumors preoperatively. MATERIALS AND METHODS Thirty-four patients with meningiomas, pituitary adenomas, vestibular schwannomas, and gliomas scheduled for resection were recruited for MR elastography. On the elastogram, the mean and the maximum shear stiffnesses were measured by placing an ROI on the tumor. Blinded to the MR elastography findings, surgeons conducted qualitative intraoperative assessment of tumor consistency by using a 5-point scale. Histopathologic diagnosis was confirmed by using the resected specimens. The mean and maximum shear stiffnesses were compared with histopathologic subtypes, and the intraoperative tumor consistency was graded by the surgeons. RESULTS The mean and maximum shear stiffnesses were the following: 1.9 ± 0.8 kPa and 3.4 ± 1.5 kPa for meningiomas, 1.2 ± 0.3 kPa and 1.8 ± 0.5 kPa for pituitary adenomas, 2.0 ± 0.4 kPa and 2.7 ± 0.8 kPa for vestibular schwannomas, and 1.5 ± 0.2 kPa and 2.7 ± 0.8 kPa for gliomas. The mean and maximum shear stiffnesses for meningiomas were higher than those of pituitary adenomas (P < .05). The mean and maximum shear stiffnesses were significantly correlated with the surgeon's qualitative assessment of tumor consistency (P < .05). The maximum shear stiffness for 5 firm tumors was higher than that of nonfirm tumors (P < .05). CONCLUSIONS MR elastography could evaluate intracranial tumors on the basis of their physical property of shear stiffness. MR elastography may be useful in discriminating firm tumors preoperatively.
Collapse
Affiliation(s)
- N Sakai
- From the Departments of Neurosurgery (N.S., H.K., T.S., H.N.)
| | | | - S Yamashita
- Diagnostic Radiology and Nuclear Medicine (S.Y., H.S.)
| | | | - H Kawaji
- From the Departments of Neurosurgery (N.S., H.K., T.S., H.N.)
| | - T Sameshima
- From the Departments of Neurosurgery (N.S., H.K., T.S., H.N.)
| | - S Baba
- Diagnostic Pathology (S.B.), Hamamatsu University Hospital, Hamamatsu, Japan
| | - H Sakahara
- Diagnostic Radiology and Nuclear Medicine (S.Y., H.S.)
| | - H Namba
- From the Departments of Neurosurgery (N.S., H.K., T.S., H.N.)
| |
Collapse
|
36
|
Saito T, Sawaki M, Hozumi Y, Sagawa N, Iwata H, Kashiwaba M, Kawashima H, Kobayashi K, Taira N, Takashima T, Takahashi M, Tsuneizumi M, Nakayama T, Baba S, Bando H, Mizuno T, Yamaguchi M, Yamamoto Y, Uemura Y, Ohashi Y, Mukai H. Abstract P4-11-09: A randomized controlled trial of postoperative adjuvant therapy for elderly breast cancer patients: Comparison of health-related quality of life between clinical trial participants and decliners. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-11-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Health-related quality of life (HRQoL) is one of the important outcomes in cancer control trials and has increasingly become the one of the primary foci. Obtaining informed consent from participants is essential for participation in randomized controlled trials (RCTs), but the participation in these RCTs may directly influence HRQoL, because treatment options are determined according to the allocation schedule. To date, only a few studies have compared HRQoL between clinical trial participants and decliners.
Patients and Method: The National Surgical Adjuvant Study of Breast Cancer 07 (N-SAS BC 07) is a randomized controlled trial in women with HER2-positive primary breast cancer who are over 70 years of age. The primary aim was to investigate the benefit of trastuzumab monotherapy compared with combination therapy using trastuzumab and chemotherapy. The study concept and design were published in concept paper (Sawaki M. et al., Jpn J Clin Oncol. 2011). In this study, patients were randomized to receive either trastuzumab plus chemotherapy or trastuzumab monotherapy. The primary endpoint was disease-free survival, and the secondary endpoints were overall survival, relapse-free survival, safety, HRQoL, comprehensive geriatric assessment (CGA) and cost effectiveness (protocol ID; NCT01104935).
HRQoL and CGA were assessed at registration (baseline), 2 month, 1 year, and 3 years after the start of protocol treatments using the Functional Assessment of Cancer Therapy-General (FACT-G), Hospital Anxiety and Depression Scale (HADS), EuroQol 5 Dimension (EQ-5D), Tokyo Metropolitan Institute of Gerontology (TMIG) index of competence, and the Philadelphia Geriatric Center (PGC) Morale Scale.
The patients who declined to participate in N-SAS BC 07 were registered in a cohort study to prospectively evaluate the subsequent treatment options and prognosis (07-Cohort). The same questionnaire that was used in N-SAS BC 07 was used in 07-Cohort to evaluate HRQoL and CGA at entry.
Results: Patients were enrolled from October 2012 to October 2016. During this period, 275 and 123 patients were registered in N-SAS BC 07 and 07-Cohort, respectively. The mean age at entry of the patients in the N-SAS BC 07 and 07-Cohort groups was 73.9 and 74.6 years, respectively. The questionnaire response rates at baseline in the patients in N-SAS BC 07 and 07-Cohort groups were 89% and 82%, respectively. There were no significant differences in FACT-G, HADS, EQ-5D, or TMIG index of competence at baseline between the groups, but the mean (standard deviation) scores of PGC Morale Scale in N-SAS BC 07 and 07-Cohort groups were 10.8 (3.3) and 9.9 (3.7), respectively, with the scores being significantly greater in the N-SAS BC 07 group (p=0.020, t-test).
Conclusion: The PGC Morale Scale provides a multidimensional approach to assess the psychological state of older people. This study indicated that participation in the RCT did not affect the baseline QoL of elderly patients but suggested that the baseline QoL of the RCT participants was better than decliners.
Citation Format: Saito T, Sawaki M, Hozumi Y, Sagawa N, Iwata H, Kashiwaba M, Kawashima H, Kobayashi K, Taira N, Takashima T, Takahashi M, Tsuneizumi M, Nakayama T, Baba S, Bando H, Mizuno T, Yamaguchi M, Yamamoto Y, Uemura Y, Ohashi Y, Mukai H. A randomized controlled trial of postoperative adjuvant therapy for elderly breast cancer patients: Comparison of health-related quality of life between clinical trial participants and decliners. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-11-09.
Collapse
Affiliation(s)
- T Saito
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - M Sawaki
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - Y Hozumi
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - N Sagawa
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - H Iwata
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - M Kashiwaba
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - H Kawashima
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - K Kobayashi
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - N Taira
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - T Takashima
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - M Takahashi
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - M Tsuneizumi
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - T Nakayama
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - S Baba
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - H Bando
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - T Mizuno
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - M Yamaguchi
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - Y Yamamoto
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - Y Uemura
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - Y Ohashi
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| | - H Mukai
- Saitama Red Cross Hospital, Saitama, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan; Kameda Medical Center, Kamogawa, Chiba, Japan; Iwate Medical University, Mrioka, Iwate, Japan; Aomori City Hospital, Aomori, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan; Okayama University Hospital, Okayama, Japan; Osaka City University Graduate School of Medicine, Osaka, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan; Mie University Hospital, Tsu, Mie, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Tokyo University Hospital, Bunkyo-ku, Tokyo, Japan; Chuo University, Bunkyo-ku, Tokyo, Japan; National Cancer Center Hospital East,
| |
Collapse
|
37
|
Deacon RS, Oiwa A, Sailer J, Baba S, Kanai Y, Shibata K, Hirakawa K, Tarucha S. Erratum: Cooper pair splitting in parallel quantum dot Josephson junctions. Nat Commun 2015; 6:10299. [PMID: 26656247 PMCID: PMC4682154 DOI: 10.1038/ncomms10299] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
38
|
Okamoto Y, Katsumata Y, Baba S, Kawaguchi Y, Gono T, Hanaoka M, Kawasumi H, Yamanaka H. Validation of the Japanese version of the Systemic Lupus Activity Questionnaire that includes physician-based assessments in a large observational cohort. Lupus 2015; 25:486-95. [DOI: 10.1177/0961203315617844] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2015] [Accepted: 10/26/2015] [Indexed: 11/17/2022]
Abstract
The Systemic Lupus Activity Questionnaire (SLAQ) is a patient-reported outcome for systemic lupus erythematosus (SLE). We aimed to translate it into Japanese and further investigate its validity and reliability. The English version of the SLAQ was translated into Japanese and administered to Japanese SLE patients at our university clinic. Physicians assessed disease activity using the SLE Disease Activity Index 2000 (SLEDAI-2K). The patients were prospectively followed for repeat assessment a year later. Ultimately, 255 patients participated. The patients’ 10-point ratings of disease activity and SLAQ scores were significantly correlated (Spearman’s ρ = 0.53). The SLAQ score was weakly correlated with the SLE Disease Activity Index 2000 (SLEDAI-2K)-nolab (omitting laboratory items; ρ = 0.18) but not with the SLEDAI-2K ( ρ = 0.02). These results suggested its convergent and discriminant validity. The SLAQ demonstrated acceptable internal consistency (Cronbach’s α = 0.80), and good test–retest reliability (intraclass correlation coefficient = 0.85). The effect sizes and the standardized response means of the SLAQ were as follows: clinical worsening, 0.26 and 0.31, and improvement, −0.39 and −0.41, respectively, which indicated a small but significant responsiveness. The Japanese version of the SLAQ demonstrated acceptable reliability and validity; its performance was comparable to that of the original version.
Collapse
Affiliation(s)
- Y Okamoto
- The Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
| | - Y Katsumata
- The Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
| | - S Baba
- The Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
| | - Y Kawaguchi
- The Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
| | - T Gono
- The Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
| | - M Hanaoka
- The Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
| | - H Kawasumi
- The Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
| | - H Yamanaka
- The Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
| |
Collapse
|
39
|
Yabuuchi H, Matsuo Y, Abe K, Baba S, Sunami S, Kamitani T, Yonezawa M, Yamasaki Y, Kawanami S, Nagao M, Okamoto T, Nakamura K, Yamamoto H, Sasaki M, Honda H. Anterior mediastinal solid tumours in adults: characterisation using dynamic contrast-enhanced MRI, diffusion-weighted MRI, and FDG-PET/CT. Clin Radiol 2015; 70:1289-98. [PMID: 26272529 DOI: 10.1016/j.crad.2015.07.004] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2015] [Revised: 07/08/2015] [Accepted: 07/08/2015] [Indexed: 01/12/2023]
Abstract
AIM To find significant parameters to characterise anterior mediastinal solid tumours in adults using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), diffusion-weighted MRI (DWI), and combined 2-[(18)F]-fluoro-2-deoxy-d-glucose positron-emission tomography/computed tomography (FDG-PET/CT). MATERIALS AND METHODS Forty-eight histologically confirmed anterior mediastinal solid tumours in 48 patients (24 men, 24 women; age range 21-83 years, mean 50.7 years) were examined. The parameters analysed were maximal diameter, presence of capsule/septa on T2-weighted images, time-signal intensity curves (TICs), apparent diffusion coefficient (ADC), and maximum standardised uptake value (SUVmax). Also examined was whether any differences between histological types could be seen in these parameters. In a validation study, 42 anterior mediastinal solid tumours in 42 patients were examined consecutively. RESULTS The washout pattern on TIC was seen only in thymic epithelial tumours (20/32). SUVmax of lymphoma (mean, 17.9), malignant germ cell tumours (14.2), and thymic carcinomas (15.6) were significantly higher than that of thymomas (6.1). The mean maximal diameter of thymic epithelial tumours was significantly smaller than that of lymphomas (p<0.01) and malignant germ cell tumours (p<0.05). The validation study also yielded high accuracy (38/42, 91%) in differentiation among the anterior mediastinal solid tumours. CONCLUSION The SUVmax, TIC pattern on DCE-MRI, and maximal diameter might be useful to differentiate anterior mediastinal solid tumours in adults.
Collapse
Affiliation(s)
- H Yabuuchi
- Department of Health Sciences, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
| | - Y Matsuo
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
| | - K Abe
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
| | - S Baba
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
| | - S Sunami
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
| | - T Kamitani
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
| | - M Yonezawa
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
| | - Y Yamasaki
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
| | - S Kawanami
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
| | - M Nagao
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
| | - T Okamoto
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
| | - K Nakamura
- Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
| | - H Yamamoto
- Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
| | - M Sasaki
- Department of Health Sciences, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
| | - H Honda
- Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
| |
Collapse
|
40
|
Ishibashi H, Nakashima Y, Baba S, Takasaki C, Kobayashi M, Okubo K. P-196PREDICTORS OF ATELECTASIS AFTER PULMONARY LOBECTOMY. Interact Cardiovasc Thorac Surg 2015. [DOI: 10.1093/icvts/ivv204.196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Ishibashi H, Baba S, Nakashima Y, Takasaki C, Kobayashi M, Okubo K. P-216CHEST TUBE REMOVAL AFTER PULMONARY LOBECTOMY: END-INSPIRATION OR END-EXPIRATION? Interact Cardiovasc Thorac Surg 2015. [DOI: 10.1093/icvts/ivv204.216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
42
|
Suzuki H, Baba S, Tsuchiyama H, Watabe T, Matsuo T. Cytoplasmic fine network and mitochondria in normal and abnormal cultured keratinocytes: an electron microscopic study using whole-cell observation technique. Curr Probl Dermatol 2015; 11:215-25. [PMID: 6197243 DOI: 10.1159/000408677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
The cytoplasmic fine structures of both normal human cultured keratinocytes (NHK) and squamous cell carcinoma cells (HSC) were examined by electron microscopy using the whole-cell preparation method and stereo-viewing techniques. The presence of cytoplasmic fine network (CFN) was confirmed in both NHK and HSC, but the structures of the two were found to be radically different. In particular, the mitochondria showed a number of distinct morphological differences. The introduction of cytochalasin B and colchicine into HSC partially destroyed the CFN, and, as a result, the morphology of the HSC mitochondria changed to become similar to those of NHK. It seems that the CFN may have an important role in determining the shape of the cell organelles, such as mitochondria, and that the shape of the mitochondria may perhaps be used as an indication of cell malignancy.
Collapse
|
43
|
Suzuki H, Hirano M, Baba S. Cytochemical studies of nuclear DNA and RNA in normal and abnormal keratinizing tissues. Curr Probl Dermatol 2015; 10:127-40. [PMID: 7238088 DOI: 10.1159/000396286] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
The distribution patterns of nuclear DNA and RNA in normal and abnormal keratinizing tissues of human skin were examined by electron microscopy, using an enzyme digestion technique. We found that the distribution of nucleic acids in the nuclei of epidermal cells during keratinization changes gradually. In the hair cells, particularly in the cells of hair cortex and Henle's layer of inner root sheath, essentially similar findings were observed. On the other hand, the distribution patterns observed in the tumor cells of calcifying epithelioma and the parakeratotic cells of psoriasis were different from each other and different from the distribution patterns of normal keratinizing tissue, hair, and epidermis. It seems that a similar pattern of reorganization of nucleic acids occurs in the nucleic of normal keratinizing cells as the cells keratinize. However, in abnormal tissue, it seems that the reorganization pattern of nucleic acids in the nuclei is different in each case.
Collapse
|
44
|
Kamarudin NHN, Jalil AA, Triwahyono S, Sazegar MR, Hamdan S, Baba S, Ahmad A. Elucidation of acid strength effect on ibuprofen adsorption and release by aluminated mesoporous silica nanoparticles. RSC Adv 2015. [DOI: 10.1039/c4ra16761a] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Mesoporous silica nanoparticles (MSN) with 1–10 wt% loading of aluminum (Al) were prepared and characterized by XRD, N2 physisorption, 29Si and 27Al NMR, FT-IR and FT-IR preadsorbed pyridine.
Collapse
Affiliation(s)
- N. H. N. Kamarudin
- Department of Chemical Engineering
- Faculty of Chemical Engineering
- Universiti Teknologi Malaysia
- 81310 UTM Johor Bahru
- Malaysia
| | - A. A. Jalil
- Department of Chemical Engineering
- Faculty of Chemical Engineering
- Universiti Teknologi Malaysia
- 81310 UTM Johor Bahru
- Malaysia
| | - S. Triwahyono
- Department of Chemistry
- Faculty of Science
- Universiti Teknologi Malaysia
- 81310 UTM Johor Bahru
- Malaysia
| | - M. R. Sazegar
- Department of Chemistry
- Faculty of Science
- Universiti Teknologi Malaysia
- 81310 UTM Johor Bahru
- Malaysia
| | - S. Hamdan
- Department of Biological Science
- Faculty of Bioscience and Bioengineering
- Universiti Teknologi Malaysia
- 81310 UTM Skudai
- Malaysia
| | - S. Baba
- Department of Biological Science
- Faculty of Bioscience and Bioengineering
- Universiti Teknologi Malaysia
- 81310 UTM Skudai
- Malaysia
| | - A. Ahmad
- Department of Chemical Engineering
- Faculty of Chemical Engineering
- Universiti Teknologi Malaysia
- 81310 UTM Johor Bahru
- Malaysia
| |
Collapse
|
45
|
Baba S, Kondo K, Toma-Hirano M, Kanaya K, Suzukawa K, Ushio M, Suzukawa M, Ohta K, Yamasoba T. Local increase in IgE and class switch recombination to IgE in nasal polyps in chronic rhinosinusitis. Clin Exp Allergy 2014; 44:701-12. [PMID: 24931597 DOI: 10.1111/cea.12287] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2013] [Revised: 01/09/2014] [Accepted: 02/03/2014] [Indexed: 01/30/2023]
Abstract
BACKGROUND Chronic rhinosinusitis with nasal polyps is generally characterized by local Th2 inflammation and is categorized into two subtypes in Japan: eosinophilic chronic rhinosinusitis (similar to chronic rhinosinusitis with nasal polyps in western countries) and non-eosinophilic chronic rhinosinusitis (characterized by Th1-dominant inflammation). OBJECTIVE To investigate local IgE production and class switch recombination to IgE in these two subtypes of chronic rhinosinusitis with nasal polyps. METHODS The identity of IgE-positive cells was determined using double-immunofluorescent staining for IgE and cell-type-specific molecular markers. To investigate the local class switch recombination to IgE and IgE synthesis in the mucosa, we performed real-time polymerase chain reaction to examine the mRNA expression of Th2 cytokines and class-switch-related molecules, including IL-4, IL-5, IL-13, ε germline gene transcripts, IgE mature transcript, IgG mature transcript, RAG1, RAG2 and activation-induced cytidine deaminase in eosinophilic polyps, non-eosinophilic polyps and controls. RESULTS The concentrations of total IgE and number of IgE-positive cells were significantly higher in the eosinophilic polyps compared with control and non-eosinophilic polyps. IgE-positive cells were predominantly mast cells in eosinophilic polyps and significantly correlated with the number of FcεR1-positive cells in the subepithelial layer. IL-5 and IL-13 mRNA and ε germline gene transcripts expression levels were significantly higher in eosinophilic polyps compared with control and non-eosinophilic polyps. In contrast, the number of plasma cells and the expression of IgG mature transcripts were increased in non-eosinophilic polyps compared with eosinophilic polyps. RAG2 mRNA was significantly increased in both eosinophilic and non-eosinophilic polyps compared with control mucosa. CONCLUSION AND CLINICAL RELEVANCE The current study suggests local class switching to IgE, production of IgE and IgE localization to the surface of mast cells in eosinophilic chronic rhinosinusitis in the Japanese population. The difference in the IgE-related profiles between eosinophilic chronic rhinosinusitis and non-eosinophilic chronic rhinosinusitis suggests heterogeneity in the pathogenesis of chronic rhinosinusitis with nasal polyps.
Collapse
Affiliation(s)
- S Baba
- Department of Otolaryngology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Yoshihara S, Kondo K, Kanaya K, Suzukawa K, Baba S, Toma-Hirano M, Kikuta S, Iwasaki Y, Fujio K, Yamasoba T. Tumour necrosis factor inhibitor-associated sinusitis. Rhinology 2014; 52:246-51. [PMID: 25271530 DOI: 10.4193/rhino13.074] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
AIM To describe the features of chronic sinusitis associated with the use of tumour necrosis factor (TNF) inhibitors. METHODOLOGY A retrospective review of the medical records between 2003 and 2011 revealed that five patients had developed chronic sinusitis after the start of TNF inhibitor administration and required rhinological evaluation and treatment. RESULTS The incidence of refractory sinusitis associated with TNF inhibitors was approximately 2%. Of the five patients identified, four patients were medicated with etanercept and one with infliximab. The maxillary sinus was most commonly involved and cultures of the sinus discharge revealed Pseudomonas aeruginosa in three cases. Two patients showed improvement of sinusitis with antibiotic medication, despite the continuous use of TNF inhibitor, while in two other patients, sinusitis was resistant to antibiotic medication. Another patient who had developed recurrence of sinusitis after complete remission of previous chronic sinusitis by endoscopic sinus surgery showed remission only after cessation of TNF inhibitor. CONCLUSION Chronic sinusitis associated with TNF inhibitors is considered to be a new disease entity, and it will become more common due to the increasing use of TNF inhibitors.
Collapse
|
47
|
Fukuda S, Baba S, Akasaka T. Psychological stress has the potential to cause a decline in the epidermal permeability barrier function of the horny layer. Int J Cosmet Sci 2014; 37:63-9. [DOI: 10.1111/ics.12169] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2014] [Accepted: 09/27/2014] [Indexed: 01/28/2023]
Affiliation(s)
- S. Fukuda
- Department of Dermatology; Faculty of Medicine; Iwate Medical University; 19-1, Uchimaru Morioka Iwate 020-8505 Japan
| | - S. Baba
- Department of Dermatology; Faculty of Medicine; Iwate Medical University; 19-1, Uchimaru Morioka Iwate 020-8505 Japan
| | - T. Akasaka
- Department of Dermatology; Faculty of Medicine; Iwate Medical University; 19-1, Uchimaru Morioka Iwate 020-8505 Japan
| |
Collapse
|
48
|
Baba S, Takanoha S, Ishiyama A, Komaki H, Takeshita E, Imaizumi H, Abe Y, Kobayashi M, Kumazawa Y, Sasaki M. G.P.179. Neuromuscul Disord 2014. [DOI: 10.1016/j.nmd.2014.06.221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
49
|
Kobayashi Y, Kariya T, Chishima J, Fujii K, Wada K, Baba S, Itoo T, Nakaoka T, Kawashima M, Saito S, Aoki N, Hayama S, Osa Y, Osada H, Niizuma A, Suzuki M, Uekane Y, Hayashi K, Kobayashi M, Ohtaishi N, Sakurai Y. Population trends of the Kuril harbour seal Phoca vitulina stejnegeri from 1974 to 2010 in southeastern Hokkaido, Japan. ENDANGER SPECIES RES 2014. [DOI: 10.3354/esr00553] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
50
|
Ota Y, Ohashi H, Otani C, Dei Y, Kondo S, Baba S. Cytomegalovirus-induced small intestinal bleeding complicated with cutaneous vasculitis: a case report. Mod Rheumatol 2014; 12:259-62. [PMID: 24387070 DOI: 10.3109/s101650200047] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract A 17-year-old woman who was being treated with prednisolone for cutaneous vasculitis developed recurrent massive melena and abdominal pain. An emergency resection was performed because of uncontrollable melena, revealing many small intestinal ulcers with cytomegalic inclusion bodies, which were found by immunopathological staining. However, the cytomegalovirus (CMV) antigenemia (CMV-Ag) assay and the IgM antibody titer for CMV were negative on admission. This case indicates that a high state of alertness for CMV infection in immunocompromised patients with gastrointestinal bleeding is required even if the CMV-Ag assay and IgM antibody are both negative.
Collapse
Affiliation(s)
- Y Ota
- Department of Internal Medicine III, Hamamatsu University School of Medicine , Handayama 1-20-1, Hamamatsu 431-3124 , Japan
| | | | | | | | | | | |
Collapse
|